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1.1 Cancer therapy 
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to 
other parts of the human body. It contains benign tumor and malignant tumor.
1
 Not all tumors could threat 
human life. Benign tumors have a slower growth rate than malignant tumors and the cells usually have 
normal features. Benign tumors are typically surrounded by a fibrous sheath or remain with the epithelium.
2
 
Although this kind of tumor lacks of the ability to invade or spread to neighboring tissue, but it still may 
cause some negative effects on human health and many types of benign tumors have the potential to become 
cancerous (malignant) through a process known as tumor progression.
3
 Malignant tumor has become one of 
the biggest threats to human life. According to the “World Cancer Report 2014” of World Health 
Organization (WHO), in 2012, there are about 14.1 million new cancer cases and 8.2 million cancer related 
deaths all over the world. And it is expected that the number of new cases will rise from 14 million in 2012 
to 22 million within the next two decades. Therefore, the huge amount of new cases and high mortality rate 
of malignant tumor make it essential and urgent to explore effective ways for cancer therapy application. 
1.1.1 Current therapies for cancer treatment and their limitations 
Over the past few decades, some methods have been developed for cancer treatment. Surgical resection 
is one of the mainly used methods in the clinical field. Tumor site could be totally removed by clinical 
surgery to prolong the patient lifetime. However, this method is only effective to the early-stage or 
middle-stage tumor, which cancer cells have not metastasized to other organs. On the other hand, the blurry 
boundary between tumor and normal tissue makes it difficult to remove the whole tumor tissue precisely. 
Because of the malignant and aggressive nature of tumor, the remained tumor cells or tumor tissue will cause 
the cancer recurrence.
4, 5
 
From 1950s, chemotherapy has been widely used as a novel way for cancer treatment. Chemotherapy is 
a strategy that using one or more kinds of anti-cancer drugs to stop or slow the growth of cancer cells. Up to 
now, there are many different types of anti-cancer drugs have been explored including alkylating agents 
(mechlorethamine, carmustine dacarbazine and so on),
6
 antimetabolites (cytarabine, gemcitabine, decitabine 
and so on),
7
 anti-microtubule agents (vinca alkaloids, taxanes and podophyllotoxin),
8, 9
 topoisomerase 
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inhibitors (etoposide, mitoxantrone, novobiocin, merbarone and so on) and cytotoxic antibiotics (doxorubicin, 
daunorobicin, dactinomycin and so on).
10
 However, all of these anti-cancer drugs lack of specificity to cancer 
cells. After injection these drugs, both tumor cells and normal cells are killed by the drugs, which could 
cause many side effects such as hair loss, immunosuppression, myelosuppression, organ damage and so on. 
What’s more, after multiple chemotherapies, the cancer cells will be resistant to anti-cancer drugs, which 
could lead to the failure of the treatment.
7
 
Radiotherapy is utilizing ionizing radiation to damage the DNA of cells to control or kill malignant 
tissue. Radiotherapy contains three main divisions: external beam radiation therapy, brachytherapy and 
systemic radioisotope therapy. However, like the chemotherapy, the main limitation of radiotherapy is lack of 
the specificity to tumor tissue. The normal tissue is also damaged during radiation, which also causes severe 
side effects.
11
 
In brief, surgical ablation, chemotherapy and radiotherapy are the most commonly used methods in the 
clinical field for cancer therapy application. Although they could kill the cancer cells and prolong the patient 
lifetime efficiently, these three methods still have many limitations such as cancer recurrence and severe side 
effects. Therefore, novel methods with high killing efficiency and specificity are highly needed. 
1.1.2 New strategies for cancer therapy application 
As mentioned, because of the limitations of current therapies, many researchers try to explore more 
effective strategies and drugs to treat malignant tumor. Up to now, some approaches have been developed. 
 
1.1.2.1 Cancer immunotherapy 
Cancer immunotherapy was firstly introduced by Steven Rosenberg and colleagues in the late 1980s. 
They reported patients with metastatic cancer possessed a low tumor regression rate (2.6–3.3%) after 
underwent active specific immunotherapy. Since then, cancer immunotherapy has drawn world-wide concern. 
Cancer immunotherapy is the use of the immune system to treat cancer (Fig. 1.1a). This approach utilized the 
fact that cancer cells often have some specific molecules on their surface, which could be detected by the 
immune system, known as tumor-associated antigens. Tumor-associated antigens are usually proteins or 
other macromolecules (e.g. carbohydrates).
12
 Cancer immunotherapy can be simply divided into active, 
passive or hybrid (active and passive) immunotherapy. Active immunotherapy is that the immune system 
directly attacked tumor cells by targeting tumor-associated antigens. Dendritic cell therapy is one kind of 
active immunotherapy. The process of provoking anti-tumor responses is that the dendritic cells present 
tumor-associated antigens to lymphocytes, which could activate lymphocytes and then the activated 
lymphocytes kill the other cancer cells that possessed the same kind of antigen.
13
 Passive immunotherapy 
enhances existing anti-tumor responses and includes the use of monoclonal antibodies, lymphocytes and 
cytokines. Antibody therapy and cytokines therapy are two kinds of passive immunotherapy. Antibody 
therapy is that monoclonal antibodies bind to target cell surfaces and form a binding region and this binding 
region can be recognized by immune system. The natural killer cells existing in the immune system could 
release some cytotoxic protein or serine protease to kill the cancer cells.
14
 Cytokines are proteins produced 
by many types of cells including tumor cells. The tumor often employs cytokines to allow it to grow and 
reduce the immune response. These immune-modulating effects let them have the potential to be used as 
drugs to raise an immune response. Interferons and interleukins are the two commonly used cytokines for 
cytokine therapy application. Nowadays, because of its low cytotoxicity, low rejection reaction and high 
specificity, more and more researchers focus on using immunotherapy for cancer therapy application.
15
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1.1.2.2 Gene therapy 
Gene therapy is the delivery of a specific gene as a therapeutic drug into targeted cells to treat diseases. 
There are several approaches of gene therapy (Fig. 1.1b). First, the copy of the health gene could replace the 
mutated gene, which causes disease. Second, the delivered gene inactivates the mutated gene and mutated 
gene could not function properly. Third, a new gene is introduced into the human body and aid to fight with 
the disease.
16
 Actually, a gene which is directly inserted into the targeted cells could not work very well. 
Therefore, a suitable carrier called a vector is genetically engineered to deliver the gene. The vectors could 
be divided into viruses and non-viral vectors (cationic polymer, liposome, polypeptide and nanoparticle). 
Virus vectors usually have better gene transfection effect than non-viral vectors, but their strong 
immunogenicity often lead the body to produce a serious rejection reaction, which resulted in the failure of 
treatment.
17
 Although the non-viral vectors do not cause strong immune rejection, low gene transfection 
efficiency, strong cytotoxicity, and poor specific targeting capacity of non-viral vectors cannot meet the 
requirements of gene delivery in the clinical field.
18
 
 
1.1.2.3 Photodynamic therapy 
Photodynamic therapy (PDT) is a kind of phototherapy involving a particular type of light and a 
photosensitizing agent. When the photosensitizing agents are exposed to a specific wavelength of light, they 
produce the molecular oxygen to destroy the cell membrane and kill nearby cells (Fig. 1.1c).
19
 PDT has been 
proven ability to kill microbial cells and some efficacy in anti-viral treatments.
20
 Clinically, PDT is widely 
used in treating severe acne
21
 and has been applied to treat a wide range of medical conditions, including 
atherosclerosis and psoriasis.
22
 Now many researchers explore the PDT to treat malignant tumors such as 
head, neck, lung, bladder and particular skin tumor.
19
 The advantage of PDT is lessening the need for delicate 
surgery, minimally invasive and minimally toxic to the human body. However, the activation wavelength of 
many kinds of photosensitizing agents is located in the ultraviolet or visible region and the penetration depth 
of ultraviolet or visible light is very limited, usually no more than one centimeter. For this reason, PDT is 
usually used to treat the tumor with small volume, skin tumor or tumor just under the skin. Because the light 
cannot pass through deeply in the tumor, PDT is less effective in treating large tumors and it is also a local 
treatment and cannot be used to treat metastasized cancer. In addition, during light irradiation, PDT can also 
cause some side effects to nearby healthy tissue such as burns, swelling, pain, and scar in the normal tissue.
23
 
Therefore, it is highly needed to develop some new photosensitizing agents that are more powerful, more 
specific to targeted cells and long-wavelength excitation that can penetrate and treat deep or large tumors. 
 
1.1.2.4 Hyperthermia therapy 
Based on the fact that cancer cells are more sensitive to high temperatures than normal cells, 
hyperthermia therapy has been developed as a new approach to induce cancer cell apoptosis or directly kill 
cancer cells by increasing the temperature of the body, particularly temperature in tumor site (Fig. 1.1d). 
Many researchers have shown that an appropriate temperature (41 ~ 47 
o
C) can damage and kill cancer cells 
and has minimal injury to normal cells and normal tissues. The tumor volume could be decreased by 
hyperthermia treatment because the high temperature could kill cancer cells and damage proteins and 
structures within cancer cells. Depending on the treated area, the hyperthermia therapy can be defined as 
local hyperthermia, regional hyperthermia and whole-body hyperthermia.
24
 Due to the difficulties of precise 
control the temperature in the tumor site, tumor hyperthermia did not have a good therapeutic efficacy, 
previously. In recent years, with the development of various technologies, a variety of new heating methods 
have been developed. It has progressively realized the exact controlling the temperature in tumor site and the 
malignant tumor can be treated efficiently. At present, the commonly studied hyperthermia methods include 
high intensity focused ultrasound (HIFU),
25, 26
 radiofrequency ablation (RFA),
27, 28
 magnetic therapy,
29, 30
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photothermal therapy (PTT)
31, 32
 and so on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. New strategies for cancer therapy (a) cancer immunotherapy, (b) gene therapy, (c) photodynamic 
therapy and (d) hyperthermia therapy. 
1.2 Photothermal therapy (PTT) 
Due to the lack of specificity to the killing of cancer cells and serious side effects on normal cells and 
normal tissues, traditional cancer treatment methods cannot achieve satisfactory cancer treatment effect. With 
the increase of the number of cancer new cases each year, the development of new high-performance and 
low toxicity of cancer treatment methods is highly needed. In recent years, photothermal therapy (PTT) has 
received extensive attention, because of its excellent therapeutic effect. Photothermal therapy is defined as 
using the photothermal conversion agents to absorb near infrared (NIR) region light and convert it to heat, 
thereby leading to the destruction of cancer cells (Fig. 1.2). The accumulation of photothermal conversion 
agents in the tumor site and selective laser irradiation of tumor tissue, photothermal therapy can effectively 
kill the cancer cells and reduce negative effect on normal tissue.
32, 33
 Therefore, it can be seen that a suitable 
photothermal conversion agent is one of the key factors of PTT. An ideal photothermal conversion agent 
should high photothermal conversion efficiency, good tumor-enriching ability and good biocompatibility. Up 
to now, many kinds of nanomaterials have been investigated as photothermal conversion agents. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. Illustration of photothermal therapy (PTT). 
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1.2.1 Photothermal conversion agent 
Photothermal conversion agent is one of the key factors of PTT. Because of the enhanced permeability 
and retention effect, nano-scaled materials (especially 20 ~ 300 nm) have aroused much attention as 
photothermal conversion agents for PTT (Fig. 1.3).
34
 
  
1.2.1.1 Iron oxide nanoparticle 
Iron oxide particles with diameters in the range of 1 and 100 nm are called iron oxide nanoparticles. 
There are two main forms of iron oxide nanoparticles, magnetite (Fe3O4) and its oxidized form maghemite 
(γ-Fe2O3).
35
 Among these two kinds of iron oxide nanoparticles, Fe3O4 nanoparticle has attracted much 
attention. Due to its superparamagnetic property, easy biodegradation, non-cytotoxicity and good 
biocompatibility, Fe3O4 nanoparticle has been extensively studied in the biomedical field and it has many 
biomedical applications.
36-38
 First, the Fe3O4 nanoparticle can be used in medical diagnosis. Fe3O4 
nanoparticle is a good contrast enhancement agent, which can be used for magnetic resonance imaging 
(MRI) to obtain high-quality anatomical images for diagnosis.
39-41
 Fe3O4 nanoparticle can be also used to 
deliver therapeutic agents to the targeted cells. Because of the high magnetic susceptibility of Fe3O4 
nanoparticles, the targeting effect of Fe3O4 nanoparticle could be improved not only by surface modification 
but also by external magnetic field that could non-invasive manipulate Fe3O4 nanoparticles in living 
body.
42-44
 Moreover, the Fe3O4 nanoparticles can be also used for magnetic hyperthermia.
30, 45-47
 When the 
injected Fe3O4 nanoparticles exposed to the magnetic field, the local temperature could be raised up quickly 
to kill the cancer cells. Furthermore, using Fe3O4 nanoparticles as photothermal conversion agents for PTT is 
another important biomedical application. Fe3O4 nanoparticles have strong NIR absorption and high 
photothermal conversion efficiency and the local temperature could be elevated quickly during NIR laser 
irradiation. Therefore, Fe3O4 nanoparticle is also a promising candidate for PTT application.
48-52
 
Coprecipitation,
53-55
 microemulsions
56-58
 and high-temperature decomposition of organic precursors
59, 60
 are 
three main methods for preparation of Fe3O4 nanoparticles. The reaction of coprecipitation method is carried 
out in an aqueous solution and this reaction can be easily operated and have short reaction time. The 
disadvantage of the Fe3O4 nanoparticles prepared by the coprecipitation method is that the nanoparticles 
usually have a wide size distribution and the Fe3O4 nanoparticles easily aggregated with each other. The 
Fe3O4 nanoparticles prepared by microemulsions and high-temperature decomposition of organic precursors 
have a narrow size distribution and regular spherical shape. But both microemulsions and high-temperature 
decomposition of organic precursors method involve organic solvent in the reaction. 
 
1.2.1.2 Gold-based nanoparticles 
Gold-based nanoparticles have become one of the most promising candidates used for PTT. The 
advantages of gold-based nanoparticles are their facile preparation, easy modification, and good 
photothermal conversion properties. Moreover, the localized surface plasmon resonance (LSPR) peaks of 
gold nanoparticles is tunable by changing the size and shape gold nanoparticles. In addition, gold-based 
nanoparticles can be also used for CT imaging and therapeutic agent delivery.
61
 However, the photothermal 
conversion efficiency of gold nanoparticles with spherical shape is not very high, because the localized 
surface plasmon resonance (LSPR) peaks of spherical gold nanoparticles with different sizes are mainly 
located in the range of 520 to 580 nm. In vivo, the penetration depth of light with these wavelengths is 
limited. Because skin and tissues have a transmission window from 650 to 900 nm and the transmission peak 
at approximately 800 nm, which is known as the “near-infrared tissue transparent window”.62, 63Therefore, 
due to the limitation of spherical gold nanoparticles in PTT application, gold nanoparticles with different 
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shape and size have been developed for PTT, such as gold nanorods,
64-66
 gold nanostars,
67-69
 gold 
nanoshells,
70-72
 gold nanocages
73-75
 and hollow gold nanospheres.
76-78
 
 
I. Gold nanorod 
Rod-shaped gold nanoparticle has been synthesized as one solution for the disparity between the 
wavelengths required to excite spherical gold nanoparticles and the in vivo transmission window. Gold 
nanorod has two LSPR peaks: stronger one in the long-wavelength region caused by its longitudinal 
direction of gold nanorod and the other one in the visible region caused by the transverse direction of gold 
nanorod. By altering their aspect ratio, the stronger LSPR peaks of gold nanorods can be tuned from 550 nm 
up to 1 μm, which could meet the requirements of PTT application. God nanorods are usually synthesized by 
a seed-mediated growth method. A typical preparation process involves two steps. First, the Au seed solution 
was prepared by a chemical reduction of HAuCl4 with citrate as a stabilizer. And then Au seed solution is 
added to the bulk HAuCl4 growth solution, which contains HAuCl4, ascorbic acid, cetyltrimethylammonium 
bromide (CTAB) and silver ions. The stability and biocompatibility of nanoparticles are also very important. 
Many molecules and polymers have been coated on the surfaces of nanoparticles to increase their stability 
such as PEG, BSA and so on. Now many researchers investigate using gold nanrod for PTT application and 
the results showed that the heat generated gold nanorods could kill the cancer cells efficiently during NIR 
laser irradiation.
64
 
 
II. Gold nanostar 
Recently, star-shaped gold nanoparticle used for PTT has been extensively studied. Gold nanostars were 
also prepared by a seed-mediated growth method. The prepared Au seed solution was dipped into growth 
solution including HAuCl4, ascorbic acid and silver ions. The sizes of gold nanostars could be varied by 
usage of diﬀerent volumes of Au seed solution. Because of their multiple branches with sharp tips, gold 
nanostars have some unique properties. For example, the LSPR peaks of gold nanostars locate in the NIR 
region and more importantly, gold nanostars have a wide absorption peak in NIR region, which means gold 
nanostars could absorb different wavelengths of NIR light and convert it into heat to raise the local 
temperature.
79
 In addition, gold nanostars have a large surface area, which also make them a good candidate 
for drug delivery.
80
 
 
III Gold nanoshell 
Gold nanoshell is one kind of localized surface plasmon resonant (LSPR) nanoparticles, which consists 
a nanoscaled silica core which is covered by an ultra-thin gold shell. The absorption and scattering properties 
of gold nanoshells can be changed by altering the ratio of the core diameter and the shell thickness. The 
LSPR peaks of gold nanoshell could be shifted to the NIR region, if increase the size of silica core and 
decrease the thickness of the gold shell. It has been reported that after the modification, gold nanoshell has 
good photothermal efficacy on treatment of head, neck and prostate cancer.
81
 
 
IV Gold nanocage 
Gold nanocage is a novel class of gold nanostructures possessing hollow interiors and porous walls and 
it was reported in 2002 for the first time. The size of gold nanocage can vary from 10 to over 150 nm. The 
LSPR peak of gold nanocage is in the NIR region, which indicates the potential use as photothermal 
conversion agent for PTT.
73, 74
 Additionally, gold nanocage is also a promising contrast agent for optical 
imaging.
82, 83
 
 
V. Hollow gold nanosphere 
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As mentioned above, the spherical gold nanoparticles do not have obvious photothermal effect during 
NIR laser irradiation, so they cannot be applied in PTT application. Hollow gold nanosphere (HGN) as a 
novel gold nanostructure has been recently appeared. This new class of gold nanostructure has spherical 
shape, hollow interior, uniform gold shell, and strong and tunable LSPR peak in the NIR region. The average 
diameter of HGNs is usually 30 ~ 50 nm. Because of the hollow interior, the thickness of the outer shell is 
about 3 ~ 6 nm. It has been reported that the hollow gold nanosphere had be successfully used for 
photothermal ablation of cancer cells both in vitro and in vivo.
76, 78
 
 
1.2.1.3 Carbon-based nanomaterials 
 
I. Carbon nanotube (CNT) 
Carbon nanotube (CNT) is a typical one-dimensional nanomaterial. CNT was discovered by Iijima et al. 
in 1991. CNTs are made of one or more layers of graphite sheet and have a hollow tubular structure. Based 
on the number of layers, CNTs are normally classified into single-walled carbon nanotube (SWNT) and 
multi-walled carbon nanotube (MWNT). CNTs have many unique properties such as high electrical 
conductivity, good mechanical property and high thermal conductivity. More importantly, SWNTs show 
non-cytotoxicity, good biocompatibility and in the near-infrared region often referred as the "biological 
window", show low light scattering, strong absorption and autofluorescence. Due to all of these properties, 
carbon nanotubes have been widely used in many fields, especially the biomedical field. The carbon 
nanotubes can be used in near-infrared fluorescence imaging
84-86
 and photoacoustic imaging.
87-89
 After the 
surface modification, the carbon nanotube is also a good drug carrier to deliver therapeutic drug into target 
site.
90-92
 Moreover, because of its high photothermal conversion efficiency in the NIR region, carbon 
nanotube could be also used as photothermal conversion agent for PTT application. A variety of researchers 
has proved that after intravenous injection, modified carbon nanotubes could accumulate in the tumor site 
and the cancer cells could be efficiently killed during NIR laser irradiation.
93-95
 
 
II. Graphene and graphene oxide 
Graphene is discovered by Geim et al. in 2004 and this finding was awarded Nobel Prize in 2010. As a 
new class of carbon-based nanomaterials, graphene possessed unique structures and properties. Graphene is 
made of a single, tightly packed layer of carbon atoms that bonded together in a hexagonal lattice and 
graphene is also a typical two-dimensional material. Graphene has many outstanding features comparing 
with other kinds of materials. Graphene is known as the thinnest, lightest and strongest material up to now. It 
is flexible and nearly transparent. Graphene also has a large surface area, excellent thermal and electronic 
conductivity. Based on all of these features, graphene has widely applications such as energy storage and 
optoelectronics. Moreover, graphene could also be used in biomedical applications. Some recent studies have 
reported that graphene was used for nerves and cardiac tissue engineering. Moreover, graphene can be used 
in gene transfection,
96, 97
 drug delivery,
98, 99
 biosensor,
100, 101
 biological imaging
102
 and PTT applications.
102, 103
 
Graphene oxide is composed of not only carbon atom but also oxygen and hydrogen in variable ratios 
and it is usually obtained by treating graphite with strong oxidizing agents. Because the existence of carboxyl 
groups and hydroxyl groups on the surfaces of graphene oxide, it is quite easy to modify their surfaces by 
covalent or non-covalent bonding. Therefore, graphene oxide also has been widely investigated for 
biological applications.
104
 Graphene oxide is also a promising candidate for PTT application, because it 
possessed quite high photothermal conversion efficiency in NIR region.
105, 106
 
 
1.2.1.4 Copper-based nanomaterials 
Copper-based nanomaterials are another very important class of photothermal conversion agents such as 
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copper sulfide (CuxSy)
107
 nanoparticle and copper selenide (Cu2-xSe) nanoparticle.
108
 Different from 
gold-based nanomaterials, the absorption peaks of copper-based nanomaterials are mainly located near 980 
nm. Researchers have reported the modified copper sulfide nanoparticles showed no obvious cytotoxicity, 
high photothermal conversion efficiency and tumor cells could be killed efficiently during laser irradiation.
109, 
110
 
 
1.2.1.5 Other photothermal conversion agents 
Besides the photothermal conversion agents mentioned above, there are some other kinds of 
nanomaterials that can be used in PTT application. Transition metal sulfide nanoparticles including 
molybdenum disulfide (MoS2) and tungsten disulfide (WS2) have strong absorption in NIR region. Therefore, 
after surface modification, transition metal sulfide nanoparticles could be applied in PTT and results have 
indicated that these nanoparticles have good therapeutic efficacy of photothermal ablation of cancer cells. 
111-114
 
Organic polymer nanoparticels have been also studied for PTT application. For example, indocyanine 
green as organic dye molecules light has a strong light absorption capacity in the NIR region, so they can be 
act as photothermal conversion agents for PTT. Moreover, indocyanine green is a safety contrast imaging 
agent, which has been approved by the US Food and Drug Administration (FDA). Some studies have proved 
that indocyanine green is a safe and efficient agent for PTT application.
115, 116
 Polypyrrole nanoparticle is 
another kind of organic polymer nanoparticle. Polypyrrole nanoparticle has strong absorption in NIR 
region.
117, 118
 Some in vitro results have shown that polypyrrole stabilized by polyvinyl alcohol could kill 
almost all of the cancer cells by 808 nm laser irradiation for 5 min.
117
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Different kinds of nanomaterials used as photothermal conversion agents. 
1.2.2 Limitations of current PTT  
PTT has emerged as a novel way to treating malignant tumors. Since many kinds of photothermal 
conversion agents have been explored, this method has been proved having good therapeutic efficacy by 
numerous experiments both in vitro and in vivo, which made PTT become a promising strategy for cancer 
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therapy application. Up to now, most of studies focus on using different kinds of free nanoparticles as 
photothermal conversion agents for PTT application. However, there are still some limitations of current PTT, 
which restrict the application of this method in clinical field. First, the specificity of current strategies for 
PTT is not so high. It is well known that one of main limitations of traditional methods is lack of specificity. 
An ideal treatment method should be just specific to tumor site, which indicates that the tumor site could be 
totally damaged and surrounded or other parts of cells and tissue are not affected by the treatment. Usually, 
free nanoparticles used as photothermal conversion agents are entered into the body by intravenous injection 
and reach the tumor site through the blood circulation. But after the injection, most of free nanoparticles are 
rapidly cleared by mononuclear phagocyte system and the remained nanoparticles preferentially accumulate 
in some normal tissues such as kidney, lung, liver and spleen rather than the tumor site, which may cause 
some side effects on the normal tissue. In order to solve this problem, researchers have prepared 
nanoparticles with targeting ability. The surfaces of nanoparticles are modified with some specific antibodies 
or targeting ligands to target tumor tissues. For the Fe3O4 nanoparticles, they can be also manipulated by 
external magnetic field to enhance their targeting ability. Although so many strategies have been explored for 
improving the targeting ability of nanoparticles, the amount of nanoparticles accumulated in tumor sites is 
still limited. Second, the killing efficiency in vivo cannot satisfy the clinical requirements. Because of limited 
amount of nanoparticles in tumor site, the cancer cells cannot be efficiently killed during NIR laser 
irradiation. Due to the aggressive and resistant nature of cancer, the remained cancer cells or tumor tissue 
could cause the tumor recurrence. If the injected amount of nanoparticles increasing, more nanoparticles will 
accumulate in healthy tissues and it will cause cytotoxicity to the normal cells and tissues.
119
 What’s more, 
repeated heating efficiency of free nanoparticles is not so high. In the clinic, because of high growth rate of 
cancer cells, repeated treatments are very necessary for preventing cancer recurrence. However, traditional 
nanoparticle-injection-based photothermal technology is hardly to achieve this goal because the small sizes 
of nanoparticles make them easily leak from tumor sites, which could affect their killing efficiency of cancer 
cells. It might be need more than one time injection to obtain good therapeutic efficacy and multiple 
injections not only make patients painful but also have negative effect on patients’ health.120 Therefore, the 
free nanoparticles need some carriers to deliver photothermal conversion agents, improve their specificity to 
tumor site and repeat heating efficiency. 
1.2.3 Carriers for photothermal conversion agent 
Due to poor specificity, limited killing efficiency and low repeat heating efficiency of current 
photothermal conversion agents, an appropriate carrier need to be explored to deliver photothermal 
conversion agents to tumor site. Some researchers have paid attention to this field. There are two mainly 
kinds of carriers of photothermal conversion agents: cell carriers and scaffold carriers. 
 
1.2.3.1 Cell carrier 
After entered into circulation system, most of nanoparticles are cleared by the mononuclear phagocyte 
system, which is a part of immune system. Therefore, in order to minimal the immune response and improve 
the specificity, some researchers explored encapsulating nanoparticles into cells to deliver nanoparticles to 
tumor site. There are some kinds of cells including macrophages
121, 122
 and stem cells
123, 124
 have been 
investigated as carriers of nanoparticles for PTT application. 
 
I. Macrophage 
Macrophage is a kind of white blood cell and an important cell type of immune system. Macrophage 
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could recognize, engulf and digest foreign substances, abnormal cells and anything else that does not have 
healthy cell specific proteins on their surfaces. This process is called phagocytosis. Macrophages recently 
received much attention in cancer therapy application. Because numerous peripheral blood monocytes were 
recruited into tumor site during tumor development and once these monocytes crossed the endothelial 
basement membrane, they differentiated into tumor associated macrophages (TAMs). And these TAMs could 
promote tumor progression and it has been reported that TAMs can constitute up to 70% of tumor mass. 
Therefore, researchers hypothesized that using these tumor natural recruited monocytes for the delivery of 
nanoparticles. Since monocytes have innate phagocytosis ability, they can be easily loaded with 
nanoparticles and the differentiated macrophages can serve as delivery vectors for therapeutic nanoparticles 
getting into those inaccessible tumor regions. Some studies have demonstrated that both in vitro and in vivo, 
the gold nanoshell laden macrophages could migrate efficiently into malignant tumor and could achieve good 
therapeutic effect by NIR laser irradiation.
125
 
 
II. Stem cell 
It is well known that stem cell is a group of undifferentiated biological cells that can generate highly 
differentiated descendant with specific function. Stem cells have three main features: self-renewal, 
proliferation, and multi-potentiality. Since 2000, a number of in vitro and in vivo studies have discovered the 
unique migratory capacity of stem cells throughout the tumor site, which is called tumor-tropic property of 
stem cells. The precise mechanism of the tumor-tropic property of stem cell is still unknown. One of possible 
reason is that some chemokines and pro-angiogenic growth factors produced in the tumor microenvironment 
may function as attractants to induce stem cells into tumor site. Another possible mechanism is that the stem 
cells are recruited to the tumor site to repair damaged tissues. Based on the tumor-tropic property of stem 
cells, many researchers initiated to study stem cell-based delivery of anticancer agents into the tumor sites. 
This kind of stem cell-based system has minimal immunogenicity property and these modified stem cells 
could easily avoid the surveillance of immune system and cross the biological barriers to get into some deep 
areas of tumor such as tumor stroma and hypoxic tumor cores. Up to now, mesenchymal stem cells and 
neural stem cells are most commonly used for stem cell-based deliver system. Nanoparticles could be also 
loaded into stem cells to be transported into tumor site for PTT application. Some studies loaded 
pH-sensitive gold nanoparticles into mesenchymal stem cells for photothermal ablation of cancer cells. These 
pH-sensitive gold nanoparticles could aggregate under mild acidic conditions, which indicated that these 
gold nanoparticles could form large-sized aggregates in cells’ endosomes, after uptake by the mesenchymal 
stem cells. Because of the large size of nanoparticle aggregates, they could prevent cell exocytosis. It could 
contribute to increasing the loading amount of gold nanoparticles in mesenchymal stem cells and retaining 
nanoparticles in tumor site for longer time. Both in vitro and in vivo results showed that it possessed high 
targeted efficiency, increased photothermal efficiency and therapeutic efficacy during NIR laser irradiation 
by using mesenchymal stem cells-delivered pH-sensitive gold nanoparticles.
123
 
 
In brief, cell-mediated photothermal conversion agent delivery is a specific target and effective 
therapeutic system for PTT application. However, the specificity to tumor site of this system still needs to be 
improved and the safety of this method needs to be evaluated. This innovative therapeutic strategy may carry 
a substantial risk of secondary malignancy of the transformation of the implanted cells. Therefore, these 
engineered cells need to be extensively characterized before they can be considered as an appropriate method 
for clinical cancer treatment. 
 
1.2.3.2 Scaffold carrier 
Besides the cell carriers as mentioned above, scaffold-based photothermal conversion agent delivery has 
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been considered as an attractive way for PTT application. In this strategy, the photothermal conversion 
agents usually nanoparticles are immobilized on the surfaces of scaffold or embedded into scaffold matrix to 
prepare a composite scaffold with photothermal ability (Fig. 1.4). This kind of scaffold can be called 
photothermal scaffold. The photothermal scaffold can not only kill the cancer cells during NIR laser 
irradiation but also help the tissue recover and regeneration after tumor ablation. 
 
 
 
 
 
 
 
 
 
Fig. 1.4. Illustration of scaffold-based carrier for PTT. 
 
1.3 Photothermal scaffold 
It is well known that scaffold is one of the key factors of tissue engineering. During tissue regeneration, 
scaffolds act as temporary template to support cell adhesion, proliferation, and differentiation and scaffolds 
also play an important role in regulation cell behavior, cell function and tissue formation. Recently, some 
researchers combined biocompatible scaffold with photothermal conversion agent usually nanoparticles to 
prepare a composite scaffold. The composite scaffold possessed photothermal ability, which meant that the 
composite scaffold could elevate local temperature during NIR laser irradiation. There are some advantages 
of using photothermal scaffolds for PTT comparing to free nanoparticles. One of main advantage of 
photothermal scaffolds is that they can be directly implanted into the tumor site. Therefore, these 
immobilized photothermal conversion agents could be specially delivered and localized to the tumor site, 
which may contribute to achieving high heating efficiency.
111, 126
 More importantly, because these 
photothermal conversion agents are immobilized on the surfaces of scaffold or embedded into scaffold 
matrix, they could be easily retained at the tumor site for relatively longer time without easy leakage than 
free nanoparticles and thus realize repeated local heating without losing photothermal efficiency for cancer 
cell ablation and this feature is particularly essential for enhancing therapeutic efficacy and preventing 
common recurrence of malignant cancer.
127
 What’ more, after tumor ablation, the subsequent tissue recovery 
and regeneration are also very important and the porous scaffolds are also support the penetration of healthy 
cells and regeneration of normal tissue.
128, 129
 
1.3.1 Requirements of scaffold 
Scaffold is a kind of three-dimensional material, which could support cell adhesion, proliferation and 
differentiation. Therefore, scaffolds should meet some requirements listed as below:
130-132
 
 
I. Biocompatibility 
Scaffolds should have noncytotoxicity and good biocompatibility to the cells and the surrounding 
tissues. And scaffolds should support cell adhesion, proliferation and differentiation. The scaffold materials 
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and their degradation by-products should be no toxicity and no negative effect on the other cells and tissues. 
Additionally, the implantation of scaffolds should not cause the immune response and inflammation. For the 
photothermal scaffolds, without NIR laser irradiation, the cells should well attach and proliferate on these 
scaffolds. 
 
II. Porous structure 
As mentioned above, one of advantages of using photothermal scaffold for PTT is that photothermal 
scaffold could not only efficiently kill cancer cells, but also support healthy cell penetration and normal 
tissue regeneration. Therefore, good pore structure of scaffolds is also very important. A scaffold with ideal 
porous structure should not only have high porosity but also many interconnected pores. The interconnected 
pore structure is beneficial to cell penetration into scaffold and homogenous distribution throughout the 
scaffolds. Moreover, the interconnected pores also contribute to adequate nutrients diffusion and waste 
transportation of cells. 
 
III. Biodegradability 
Scaffolds should be biodegradable in vivo environment and degradation rate should match the rate of 
new tissue formation. Finally, the implanted scaffold should be replaced by the new formed tissue. 
 
IV. Mechanical property 
The appropriate mechanical property of scaffolds is needed because scaffolds should be strong enough 
to resist surgical handling and withstand the contraction force of cells. What’s more, the mechanical property 
of scaffolds should be also matched the implanted site. 
1.3.2 Biomaterials for scaffold fabrication 
Choosing an ideal biomaterial for scaffold fabrication is very important for biomedical applications. 
Large amounts of materials have been developed for scaffold preparation. Typically, there are three main 
kinds of biomaterials used for the fabrication of scaffolds, synthetic polymers, natural polymers and ceramics. 
Each kind of these biomaterials has their own advantages in tissue repair and regeneration. 
 
1.3.2.1 Synthetic polymers 
Biodegradable synthetic polymers used for scaffold fabrication have many advantages over other 
materials. One of key advantages is that the mechanical properties and degradation rate can be tailored to suit 
different applications. Moreover, it is easy for synthetic polymers to be processed into different shapes and 
modified with designed functional groups on the polymer chains. Many kinds of synthetic polymers have 
been developed for biomedical application, such as polyesters, polyanhydrides, polyurethanes and so on. 
Among all of these synthetic polymers, the most commonly investigated biodegradable synthetic polymers 
are polyesters and polyanhydrides. 
Poly(glycolic acid) (PGA), poly(lactic acid) (PLA) and their copolymers poly(lactic acid-co-glycolic 
acid) (PLGA) are the most commonly used biodegradable polyesters in the biomedical fields.
133, 134
 PGA is 
biodegradable, thermoplastic polyester with the simple linear structure. PGA could be easily hydrolysis due 
to the existence of ester linkage in its backbone. Therefore, the degradation time of PGA is quite short and 
PGA could be totally degraded after 4 weeks implantation. PLA is biodegradable and bioactive polyester 
derived from many renewable resources, such as starch and sugarcane. Because of the hydrophobicity of 
PLA, the degradation time of PLA is much longer than PGA. Usually, PLA takes more than two years for 
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complete absorption by human body in vivo environment. Therefore, their copolymer PLGA was developed 
to meet different application requirements. The degradation time could be easily changed by varying the 
monomer ratio GA and LA. When the monomer ratio of GA and LA is 50:50, the copolymer PLGA has 
fastest degradation rate and it takes about two months for complete degradation. Due to the advantages of 
these biodegradable polymers, PGA, PLA and PLGA has been investigated for biomedical applications such 
as tissue engineering, drug delivery and nanomedicine. Moreover, PLA has been used in clinical field to 
make screws and darts for meniscal repair, which is named Clearfix Mensical Dart/Screw. However, using 
these biodegradable polymers for biomedical applications still faces some challenges. For example, PGA, 
PLA or PLGA may cause some local inflammatory response and rejection, which is contributed to their 
massive release of acidic degradation by-products. 
Polyanhydrides are a class of biodegradable polymers, which contain repeat anhydride bonds linked 
with polymer backbone chain. Because the degradation product of polyanhydrides is diacid monomers, 
which is non-toxic, biocompatible and could be metabolized and eliminated from the body, the main 
application of polyanhydrides is in the biomedical fields, such as drug delivery, medical products, 
pharmaceutical industry.
135, 136
 Gliadel is a biomedical product made of polyanhydrides, which has been used 
in clinical field to treat brain cancer. The degradation time of polyanhydrides can be varied from days to 
years depending on the different composition. Due to their acidic degradation by-products, polyanhydrides 
could still cause some undesirable side effects after implantation. 
 
1.3.2.2 Natural polymers 
Natural polymers are another important class, which could be used for the fabrication of porous 
scaffolds. Natural polymers for biomedical applications have many advantages comparing with synthetic 
polymers. One of the major advantages of natural polymers is that they possessed some biochemical cues 
(arginine-glycine-aspartic (RGD)), which are beneficial to cell attachment and proliferation. And natural 
polymers are also biodegradable and the degradation products usually do not cause some toxic side effects. 
Many kinds of natural polymers have been developed for porous scaffolds fabrication such as collagen, 
gelatin, chitosan, silk fibroin and so on. 
 
I. Collagen 
Collagen is a natural protein, which is one of the main components of extracellular matrix (ECM) in 
normal tissues and collagen is the most abundant protein in human body, making up about 30% in the whole 
protein content. Up to now, there are about 28 types of collagen has been explored. But in human body, the 
content of type I collagen is over 90%. The basic structural unit of collagen is three amino acids glycine, 
proline, and hydroxyproline with a triple helix structure stabilized by hydrogen bonds. These collagen 
molecules pack together to form collagen fibrils, and then further assemble with each other to form collagen 
fibers to support cells and tissues. Collagen used as scaffold materials has been intensively studied. The 
results showed the collagen-based porous scaffold possessed good biocompatibility and biodegradability. 
However, because collagen is derived from different sources, it may cause some antigenic and immunogenic 
response after implantation in vivo.
137
 
 
II. Gelatin 
Gelatin is derived from collagen through hydrolyzing treatment of collagen. Using gelatin for 
preparation of porous scaffold has many advantages. First, because the same amino acid sequences as 
collagen, gelatin also has excellent biocompatibility, biodegradability and cell recognized RGD sequence, 
which could significantly improve infiltration, adhesion, spreading, and proliferation of cells in resulting 
scaffolds. Moreover, gelatin is a denatured product of collagen so it has much less antigenicity and 
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immunogenicity than collagen. In addition, gelatin is low-cost and easily available, which could be obtained 
from various sources such as porcine, bovine and fish. Gelatin can be categorized into type A gelatin and 
type B gelatin. Type A gelatin is obtained by using acid hydrolysis of collagen and its isoelectric point is at 
pH 7 ~ 9. Type B gelatin is obtained by using alkaline hydrolysis of collagen and its isoelectric point is at pH 
4 ~ 5. A low temperature can lead the gelation of gelatin usually at 0 ~ 25 ºC, the exact gelation temperature 
of gelatin solution is dependent on the gelatin sources and concentration of gelatin solution. The higher the 
concentration of gelatin solution leads more quickly gelation at the same temperature. Porous gelatin 
scaffolds have been fabricated for different tissue regeneration such as skin,
138, 139
 bone
140, 141
 and cartilage.
142, 
143
 And the results confirmed porous gelatin scaffold could support and improve the cell attachment, 
proliferation and differentiation, which made it an ideal material for tissue recover and regeneration. 
 
III. Chitosan 
Chitosan is a kind of polysaccharide, which is derived from chitin, containing repeating units of 
D-glucosamine and N-acetyl-D-glucosamine. When the ratio of D-glucosamine number in chitin is over 50%, 
chitin becomes soluble in aqueous acid solution, which is called chitosan. Chitosan has been widely used in 
different fields, especially in biomedical fields. Recently, chitosan has been approved in the United States 
and Europe for use as bandages and hemostatic agents because its ability to quickly stop bleeding. Moreover, 
Chitosan is also a good drug carrier. Chitosan could become positive charge in acid solution because of the 
protonation of its amine groups and this positive charge could be maintained in neutral pH. Therefore, using 
chitosan for drug delivery could enhance the adsorption of drugs.
144
 What’ more, the chitosan-based porous 
scaffolds have been developed. Porous chitosan sponges are prepared for tissue engineering. The results 
showed chitosan-based porous scaffolds possessed good biocompatibility and could promote cell attach, 
proliferation and osteogenic differentiation of MSC cells.
145
 
 
IV. Silk fibroin 
Silk fibroin is a natural polymer obtained from various sources such as silkworms, spiders, and flies. 
Silk fibers could be obtained from diverse sources such as spiders, silkworms, scorpions, mites and flies. The 
structural units of silk fibroin are repeating amino acid sequences (Gly-Ser-Gly-Ala-Gly-Ala)n. Among all of 
these silk fibroins, silk of silkworms is a promising scaffold material, which possesses good biocompatibility, 
suitable mechanical properties. In vivo, it takes about a few weeks for silk fibroin-based porous scaffolds 
disintegrating and after one year, the silk fibroin-based porous scaffolds could be completely degraded and 
absorbed.
146
 Moreover, massive functional groups in the side chains of silk fibroin could be easily modified 
with some bioactive molecules and growth factors. It has been reported that RGD modified silk fibroin could 
promote the attachment, spreading, proliferation and differentiation of MSCs.
147
 However, fibroin cannot 
dissolve in water and can be only dissolved in salt-containing aqueous solution and organic solvents. 
 
1.3.2.3 Ceramics 
Ceramic is an inorganic, nonmetallic solid material. In the biomedical field, the most commonly used 
ceramics are hydroxyapatite (HA) and beta-tricalcium phosphate (β-TCP). These bioceramics has been 
extensively studied for tissue regeneration, especially in bone tissue engineering, because they are similar to 
the inorganic component of and possessed excellent mechanical properties. It has been demonstrated that 
bioceramic porous scaffolds had not only good biocompatibility but also osteoconductive and osteoinductive 
properties on cell proliferation and differentiation.
148
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1.3.3 Preparation methods for porous scaffolds 
As mentioned above, an ideal porous scaffold should not only have high porosity but also many 
interconnected pores. Most commonly used preparation methods for porous scaffolds can be categorized into 
fiber-related techniques, solid freeform methods and porogen-based methods.  
 
I. Fiber-related techniques 
Electrospinning is the most used fiber-related technique to prepare three-dimensional porous fiber mesh. 
Electrospinning is using electric force to produce charged fibers of polymer solutions with diameters ranging 
from several nanometers to micrometers. The electrospinning device contains a high voltage supplier, a 
syringe pump and a metal collector. Many kinds of polymer including natural polymer (collagen, cellulose, 
silk fibroin and so on) and synthetic polymer (PLGA, PLA, polyurethanes and so on) can be used this 
technique to prepare polymer fiber scaffolds. The advantages of this technique are that the prepared fiber 
scaffolds possessed high surface-to-volume ratio, tunable porosity, variable sizes and shapes and easy control 
the fiber composition to achieve desired properties and functionality. However, it still has some limitations. 
The pore size of electrospinning fiber mesh is too small Therefore, it is difficult for cells to penetrate or 
migrate into scaffold, resulting in the non-uniform cell distribution throughout the scaffolds. Moreover, the 
thickness of scaffold prepared by electrospinning is limited usually hundreds micrometers, which is not the 
truly three-dimensional structure. Additionally, the residue of organic solvent may have some toxicity to the 
cells.
149
 
 
II. Solid freeform methods 
Solid freeform methods can fabricate the scaffolds that have the complex structure. Usually, solid 
free-form methods usually contain two types of systems. One type is laser-based system such as selective 
laser sintering and stereolithography. The other type is printing-based system such as 3D printing. Now, 
using 3D printing to construct porous scaffolds has attracted growing interest. The pore structure including 
pore size, shape and porosity can be easily controlled by using 3D printing. Moreover, the printed pores are 
well interconnected, which is critical for cell distribution, penetration and tissue regeneration. What’s more, 
3D printing method can fabricate the porous scaffolds with different thickness and shape to meet the 
different application requirements. However, the limitations of 3D printing are that this technique requires 
expensive equipment, high printing temperature and limited kinds of material that can be printed by this 
technique.
150
 
 
III. Porogen-based methods 
In this method, porogens were thoroughly mixed with material solution and many kinds of porogen 
have been explored such as carbon dioxide (CO2) gas, water, sodium chloride particles, paraffin 
microspheres and ice particulates.
151
 After complete removal of the porogen in the mixture, a porous scaffold 
can be obtained. Most commonly used strategies of this method are gas foaming, particulate leaching and 
freeze-drying. 
The typical preparation process of porous scaffold prepared by gas foaming is that first the polymer 
disks such as PLA, PGA or PLGA can be prepared by using heating and compression, or by drying a 
polymer solution. Then the polymer disk is put in a chamber filled with high pressure CO2 and equilibrated 
for more than 72 h at room temperature. Finally the CO2 in the chamber releases within 15 seconds to attain 
the atmospheric pressure and the CO2 gas in the polymer disk nucleate and form bubbles resulting in a highly 
porous scaffold. By using this method, porosity of polymer scaffolds can be as high as 93%. However, there 
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are still some limitations of this method. Although high porosity can be achieved, the pores created by this 
method are usually closed and lack of good interconnectivity.
152
  
Particle leaching method can make the porous scaffolds with controlled porosity and pore size by 
adjusting the ratio and size of porogen. Typically, polymer solution is homogenously mixed with porogen 
then the mixture is put in a designed mold. After removal of porogen, the porous polymer scaffolds can be 
formed. Many kinds of materials can be acted as porogen such as the inorganic particles such as sodium 
chloride particles and organic particles such as paraffin, alginate or gelatin microspheres. The removal of 
these porogen can be achieved by dissolving porogen in an approperiate solvent such as water for sodium 
chloride particles or aliphalic solvent for paraffin microspheres. This method has been widely used to 
prepare porous scaffolds with controlled pore structure.
153
 However, the thickness of porous scaffolds 
prepared by this method is limited because of the need of complete removal of porogen in polymer matrix. 
Moreover, the independent porogen cannot connect with each other indicating the poor interconnectivity of 
porous scaffolds. What’s more, In addition, the incomplete removal of porogen and solvent residue may lead 
cytotoxicity to cells or decrease the efficacy of bioactive molecules. 
Freeze-drying is one of the most commonly used methods for porous scaffolds preparation. This method 
usually comprises two stages. First, the polymer solution freezes at low temperature and ice crystals are 
formed in the freezing process. And then the surrounding pressure reduces and the frozen water in the 
material directly sublimate directly from the solid phase to the gas phase to form the pores in the scaffolds.
154
 
However, the main problem of this method is the random pore structure formed in the polymer matrix. 
Recently, ice particulate have emerged as an ideal porogen material which combines the particle 
leaching and freeze-drying strategies to prepare porous polymer scaffolds (Fig. 1.5). Because the ice 
particulates are made of water, there is no toxicity to the cells or bioactive molecules. Moreover, the size of 
ice particulates can be easily controlled by the purchased sieves. By varying the adding amount of ice 
particulates, the porosity can be also changed. More importantly, during freezing process, many small ice 
crystals were in-situ formed around the added large ice particulates and they could also serve as porogen. 
After freeze-drying, many small pores are formed and connect the spherical large pores with each other, 
which could significantly improve the interconnectivity of porous scaffolds. Previous studies have proved 
that the cells can be homogenous distributed not only on the surfaces but also inside the porous scaffolds by 
using ice particulates as porogen and the homogenous cell distribution could beneficial to the subsequent 
tissue regeneration.
155, 156
   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5. Ice particulates as porogen for preparation of porous scaffolds. 
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1.4 Motivation, objectives and outline 
1.4.1 Motivation and objectives 
Comparing with the traditional methods for cancer treatment, PTT is a new strategy for cancer treatment 
with non-invasive and excellent therapeutic efficacy. However, low specificity and easy diffusion of 
nanoparticles which are the mainly used as photothermal converision agents restrict the current PTT for 
clinical applications. Recently, photothermal scaffolds have emerged as carriers to deliver photothermal 
conversion agents for efficient PTT. Using photothermal scaffolds for PTT have some advantages comparing 
with free nanoparticles such as the high specificity and excellent repeating heating efficiency. What’s more, 
the photothermal scaffolds can also help the tissue recover and regeneration after tumor ablation. Up to now, 
there are some studies reported using nanoparticle-immobilized scaffolds for PTT application. However, 
most of the studies are using electrospinning scaffolds or injectable hydrogel for PTT and these kinds of 
scaffolds are lack of interconnected porous structure for cells penetration and regeneration after cancer cell 
ablation. Moreover, after the tumor ablation, there may be still some cancer cells remained, which could lead 
cancer recurrence. Therefore, a multifunctional photothermal scaffold with cancer cell capture ability is 
highly needed. Inspired by all of these issues, the objective of my study is to prepare porous photothermal 
scaffolds with high photothermal efficiency and cancer cell killing efficiency for PTT applications. Moreover, 
the specifically capture and kill cancer cells by the implanted photothermal scaffolds were also studied. 
Because the properties of immobilized photothermal conversion agents could affect the heating efficiency, 
the influence of nanoparticles properties on therapeutic efficacy of photothermal scaffolds was compared and 
discussed. 
 
1.4.2 Outlines 
In this study, porous gelatin (Gel) scaffolds were prepared as a carrier to deliver photothermal 
nanoparticles. The porous Gel scaffolds were prepared by a facile ice particulate templating method. 
Different kinds of photothermal conversion agents including iron oxide nanoparticles (Fe3O4) and gold 
nanoparticles were incorporated into porous Gel scaffolds for photothermal ablation of cancer cells. 
In chapter 2, porous gelatin/iron oxide (Gel/Fe3O4) composite scaffolds were prepared by using ice 
particulates as porogen. The killing efficiency and repeated therapeutic efficiency of Gel/Fe3O4 composite 
scaffolds for cancer cells were studied by NIR laser irradiation.  
In chapter 3, folic acid (FA), which could be used as a cancer cell targeting ligand, were introduced into 
porous Gel/Fe3O4 composite scaffolds to enhance the cancer cell capture ability of scaffolds. The capture 
efficiency and killing efficiency of Gel/Fe3O4-FA scaffolds with different FA grafting density were 
investigated 
In chapter 4, porous composite scaffolds of Gel and gold nanoparticles with tunable particle size and 
shape were prepared for PTT application. The heating efficiency and killing efficiency of composite 
scaffolds with different gold nanoparticles size and shape were compared and discussed. 
Chapter 5 gives the general conclusions and future perspective of this thesis. 
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Preparation of gelatin/Fe3O4 composite scaffolds for enhanced and 
repeatable cancer cell ablation 
 
 
 
 
2.1 Summary 
Various nanomaterials have been extensively investigated for photothermal ablation of cancer cells 
because of their high photothermal conversion efficiency. However, the poor targeting specificity and low 
repeated heating efficiency of nanomaterials restrict their applications in clinic. In this work, porous 
gelatin/iron oxide (Gel/Fe3O4) composite scaffolds were prepared by a facile ice particulates templating 
method for efficient and repeatable cancer cells ablation. Gel/Fe3O4 composite scaffolds showed controlled 
porous structure consisting of large pores and interconnecting small pores. The strong absorption in the 
near-infrared (NIR) region enabled the Gel/Fe3O4 composite scaffolds to elevate local temperature quickly 
under NIR laser irradiation. The composite scaffolds allowed cell adhesion and proliferation showing good 
biocompatibility. Cancer cells entrapped in the scaffolds could be efficiently killed during laser irradiation. 
Moreover, the therapeutic efficacy of Gel/Fe3O4 composite scaffolds could be enhanced by repeated laser 
irradiation treatment, which is important for clinical application because of the resistant and recurrent nature 
of cancer. The results indicated the porous Gel/Fe3O4 composite scaffold had good biocompatibility and 
excellent cancer cells ablation efficacy, which may provide an attractive way to use porous scaffolds for 
cancer therapy application. 
2.2 Introduction 
Cancer has become one of the biggest threats to human health. According to the World Health 
Organization (WHO), each year about 8 million people die of cancer all over the world. Up to now, surgical 
resection, chemotherapy and radiotherapy are the most commonly used methods in the clinical field to treat 
cancer. However, these methods still face some challenges such as cancer recurrence and side effects.
1-4
 In 
recent years, photothermal therapy (PTT) as a novel treatment for cancer has attracted increasing attention.
5-7
 
PTT uses the photothermal conversion agents to absorb near infrared (NIR) light and convert it to heat, 
thereby leading to the destruction of cancer cells.
8-10
  
Many nanomaterials can be used as PTT agents, such as iron oxide (Fe3O4) nanoparticles,
11-16
 carbon 
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nanotubes,
17-19
 graphene
20-22
 and gold-based nanomaterials.
23-25
 Among all of these PTT agents, Fe3O4 
nanoparticles have aroused much attention due to their unique properties and good biocompatibility.
26-28
 
Beneficial from the strong NIR absorption and high photothermal conversion efficiency, Fe3O4 nanoparticles 
can raise up the local temperature quickly to kill cancer cells with exposure to the NIR laser.
11, 13
 Moreover, 
high magnetic susceptibility of Fe3O4 nanoparticles enables their non-invasive manipulation in living body 
by external magnetic fields.
29, 30
 However, applications of Fe3O4 nanoparticles for cancer diagnosis and 
therapy still have some challenges. For example, the accumulation of Fe3O4 nanoparticles into tumor sites is 
still limited although many targeting strategies have been applied, such as magnetic targeting and molecular 
targeting.
12, 31
 After the intravenous injection, most of Fe3O4 nanoparticles are rapidly cleared by 
mononuclear phagocyte system and preferentially accumulated in some organs such as kidney, liver and 
spleen rather than the tumor site.
32
 Furthermore, if these nanoparticles are locally injected into tumor site, 
their small sizes make them easily leaked from the tumor site.
33
 All of these issues lower the photothermal 
efficacy of nanoparticles. Therefore, it is essential to develop a Fe3O4-based PTT material with excellent 
local photothermal efficacy. 
Recently, a strategy that immobilizes PTT agents on implanted substrate has emerged for effective 
photothermal therapy application.
32, 34-39
 The advantage of immobilized PTT agents is that they can be 
efficiently localized to the tumor site.
36, 40-42
 More importantly, they can be easily retained at the tumor site 
for relatively longer time than free nanoparticles and thus realize repeated local heating without losing 
photothermal efficiency for cancer cells ablation, which is particularly critical for treating the recurrence of 
cancer.
33
 
In this study, composite porous scaffolds of Fe3O4 and gelatin (Gel) were prepared by using ice 
particulates as porogen for localized photothermal ablation of cancer cells. Ice particulates were used to 
control the pore structure and increased pore interconnectivity, which were important for cancer cells 
entrapment. The Gel/Fe3O4 composite scaffolds showed an obvious absorption of NIR light and the local 
temperature could be elevated quickly under NIR laser irradiation. In vitro studies showed the Gel/Fe3O4 
composite scaffolds had good biocompatibility and excellent photothermal therapeutic efficacy. Furthermore, 
the cancer cell killing efficiency of Gel/Fe3O4 scaffolds could be improved by repeated irradiation. 
2.3 Materials and methods 
2.3.1 Materials  
Iron (III) chloride hexahydrate (FeCl3•6H2O, 97%), sodium sulfite (Na2SO3, 98%), 2-(Nmorpholino) 
ethanesulfonic acid (MES), Eagle’s Minimun Essential Medium (EMEM), penicillin, streptomycin 
trypsin/EDTA and DNA quantification kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Trisodium citrate dihydrate (C6H5Na3O7 ･ 2H2O,) 25 wt% ammonia solution, acetic acid and 
N-hydroxysuccinimide (NHS) were purchased from Wako Pure Industries, Ltd (Tokyo, Japan). Porcine 
derived gelatin was provided by Nitta Gelatin (Osaka, Japan). 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) was purchased from Peptide Institute, Inc. (Osaka, Japan). WST-1 reagent was obtained 
from Roche Molecular Biochemicals (Mannheim, Germany). A cellstain live-dead double staining kit was 
purchased from Dojindo Laboratories (Kumamoto, Japan). All the chemicals and materials were used as 
received without further purification. The water in all experiments was purified using a Q-POD Milli-Q 
water purification system (Millipore Corp., Billerica, MA, USA) with a resistivity of 18.2 MΩ•cm. 
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2.3.2 Synthesis of the Fe3O4 nanoparticles  
Fe3O4 nanoparticles were synthesized according to a previously reported method with some 
modifications.
43
 Briefly, a Na2SO3 (0.4 g in 20 mL water) solution was mixed with a FeCl3•6H2O (2.6 g in 40 
mL water) solution under nitrogen atmosphere protection. Subsequently, the mixture solution was transferred 
into a 75 
o
C water bath, followed by the addition of 4 mL ammonia solution (25 wt%) and 10 mL citrate 
solution (0.1 g/mL). After reaction for 40 min, the solution was cooled down to room temperature and then 
the formed Fe3O4 nanoparticles were collected by magnetic separation, washed four times with water and 
finally dispersed in water and stored at 4 
o
C for further use. 
2.3.3 Preparation of Gel/ Fe3O4 composite scaffolds  
Gel/Fe3O4 composite scaffolds were prepared by using pre-prepared ice particulates as a porogen 
material.
44
 Briefly, an 8 wt% Gel solution was firstly prepared by dissolving appropriate amount of Gel into 
an acetic acid solution. The Fe3O4 nanoparticle suspension solution of different concentration was mixed with 
the same volume of Gel acetic acid solution under mechanical shaking. After that, the mixture solutions 
(containing 4 wt% Gel) were sonicated for 30 min at room temperature and then put at -4 
o
C for 40 min for 
temperature balance.  
Ice particulates were prepared by spraying pure water into liquid nitrogen. The ice particulates with 
diameters in a range of 425 ~ 500 µm were obtained by sieving the formed ice particulates with two sieves 
having mesh pores of 425 and 500 µm. The ice particulates were then transferred into a cooled glass bottle 
and kept at -4 
o
C for 2 h for temperature balance. After that, the ice particulates were mixed thoroughly with 
the cooled Gel-Fe3O4 mixture solution at a weight/volume ratio of 7:3 (g/mL) at -4 
o
C. Subsequently, the 
mixture of Gel-Fe3O4 solution and ice particulates was poured into a cooled silicone frame to control 
dimension of the composite scaffold. The entire set was first pre-frozen at -20 
o
C for 12 h and then 
transferred to -80 
o
C for 4 h for further frozing. Finally, the entire set was freeze-dried for 3 d. 
After freeze-drying, the formed composite scaffolds were washed with ethanol (99.5%) for 10 times to 
remove residual acetic acid. After washing with ethanol, the composite scaffolds were cross-linked with 
EDC and NHS ethanol aqueous solution. To protect the dissolution of collagen and maximize the 
cross-linking effect, three mixture solvents with a decreasing ethanol concentration (ethanol/water=95/5, 
90/10, 85/15, v/v) were used to prepare the crosslinking solutions, which contained 50 mM EDC, 20 mM 
NHS and 0.1 (wt/v)% MES. The Gel/Fe3O4 composite scaffolds were crosslinked sequentially by the three 
crosslinking solutions of a decreasing ethanol concentration (from 95/5, 90/10, 85/15) for every 8 h in each 
solution. After cross-linking, the composite scaffolds were rinsed with water for 6 times and then further 
treated with 0.1 M glycine for 6 h. Finally, the scaffolds were washed with water and freeze-dried for 2 d to 
get the final Gel/Fe3O4 composite scaffolds. The porous Gel scaffold was also prepared by the same method 
without adding Fe3O4 nanoparticles. The Gel/Fe3O4 composite scaffolds prepared with a weight ratio of 
Fe3O4 nanoparticles to dry composite scaffold of 1 wt%, 5 wt%, 10 wt% and 15 wt% were denoted as 
Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15, respectively. 
2.3.4 Characterization of Fe3O4 nanoparticles and Gel/Fe3O4 scaffolds  
Size and morphology of as-synthesized Fe3O4 nanoparticles were investigated by transmission electron 
microscopy (TEM, JEOL 2011F, Japan). The Fe3O4 nanoparticle size was determined by measuring more 
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than 100 nanoparticles in different TEM images using an ImageJ software. Dynamic light scattering (DLS) 
was used to measure the hydrodynamic size of the Fe3O4 nanoparticles. X-ray powder diffraction (XRD) 
analysis was carried out with a Rigaku X-ray diffractometer operating with Cu Kɑ radiation (λ = 0.1541 nm) 
at a scanning rate of 3 
o
/min to investigate the crystalline structure of Fe3O4 nanoparticles, Gel scaffolds and 
Gel/Fe3O4 composite scaffolds. The pore structures of Gel scaffolds and Gel/Fe3O4 composite scaffolds were 
observed by a scanning electron microscope (SEM, Hitachi S-4800, Japan) and the pore size was measured 
from SEM images by an Image J software. Four images of each scaffold and at least 20 pores per image were 
used for the pore size analysis. All the scaffolds were cut into cylinder shape (Φ6.0 × H5.0 mm) to measure 
the porosity of Gel scaffolds and Gel/Fe3O4 composite scaffolds (n = 3). And the porosity was calculated 
according to the following formula: porosity = Vpore/V = ((W2–W1)/ρ/V) × 100%, where Vpore is the volume 
of pores, V is the total volume of the scaffold, W1 is the dry weight of the scaffold, W2 is the weight of 
scaffold with water and ρ is the density of water. 45, 46 The volume of the scaffolds was calculated from the 
scaffold dimension. The quantity of Fe3O4 nanoparticles incorporated in the composite scaffolds was 
determined via thermogravimetric analysis (TGA, Seiko Exstar 6000 TG/DTA 6200 thermal gravimetric 
analyzer, Tokyo, Japan). UV-visible absorption spectra of the samples were recorded using a UV-2600 
UV-visible spectrophotometer (Shimadzu Corp., Japan).  
2.3.5 Photothermal effect of the Gel/Fe3O4 composite scaffolds  
To investigate the photothermal effect of the Gel/Fe3O4 composite scaffolds, samples filled with culture 
medium (EMEM) were exposed to a NIR laser (805 nm, Thorlabs Inc., USA) with a power density of 1.6 W 
cm
-2
 for 180 s. During the irradiation, a digital thermometer (AS ONE Corp., Japan) was used to measure the 
temperature of the samples every 10 s. 
2.3.6 Cell culture in the scaffolds 
HeLa cells (Human cervical carcinoma cell line) were cultured in a regular EMEM medium 
supplemented with 10% FBS, penicillin (100 U mL
-1
) and streptomycin (100 μg mL-1) in 5% CO2 incubator 
at 37 
o
C in a humidified environment. The cells were seeded in 75 cm
2
 tissue culture flasks and passaged 
using a 0.25% trypsin-EDTA solution after reaching confluence. 
The Gel scaffolds and Gel/Fe3O4 composite scaffolds were cut into cubes (5 × 3 × 1 mm
3
), sterilized 
with 70% ethanol, washed with PBS for 5 times and immersed into culture medium at 37 
o
C for 6 h. After 
removing the culture medium from the scaffolds, 1 × 10
5
 HeLa cells were seeded into each scaffolds. After 5 
h of incubation, the cell/scaffold constructs were transferred into 6-well plates and cultured in medium at 37 
o
C and 5% CO2 incubator. 
2.3.7 Cell adhesion and proliferation in the composite scaffolds 
The adhesion and proliferation of HeLa cells were measured to determine the biocompatibility of Gel 
scaffolds and Gel/Fe3O4 composite scaffolds. After being cultured for 1 d, cell/scaffold constructs were fixed 
with 2.5% glutaraldehyde at room temperature for 2 h. The fixed constructs were washed with MilliQ water 
thoroughly and freeze-dried. SEM was used to observe the cell adhesion and distribution in the Gel scaffolds 
and Gel/Fe3O4 composite scaffolds. DNA amount was used to determine cell proliferation in the Gel 
scaffolds and Gel/Fe3O4 composite scaffolds. After being cultured for 1, 3 and 7 d, the cell/scaffold 
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constructs were harvested, washed with water, freeze-dried and digested with papain solution. DNA content 
in the Gel and Gel/Fe3O4 composite scaffolds was measured with Hoechst 33258 dye and quantified by a 
spectrofluorometer (FP-6500, JASCO, Japan).
47
 Every three samples were used for the measurement to 
calculate the average and standard deviation. 
2.3.8 In vitro photothermal ablation of HeLa cells 
In vitro photothermal ablation of cancer cells was carries out by NIR laser irradiation (805 nm, Thorlabs 
Inc., USA). The power density of laser was adjusted to 1.6 W/cm
2
. After 24 h of culture, cell/scaffold 
constructs were divided into irradiation groups (with laser irradiation) and non-irradiation groups (without 
laser irradiation). For the irradiation group, cell/scaffold constructs were taken out from the culture dishes 
and exposed to the NIR laser for 3 min. The samples without laser irradiation were also taken out from the 
dishes for 3 min to exclude environmental effects on cell death. After the laser irradiation, all of the 
cell/scaffold constructs were continuously cultured for another 5 h. Cell viability were measured by a WST-1 
assay. The absorbance at 440 nm was measured by a microplate reader (Benchmark Plus, Bio-Rad, Hercules, 
CA, USA). In order to check the repeated photothermal effect of Gel/Fe3O4 scaffolds during repeated NIR 
laser irradiation, the cell/scaffold constructs were exposed to NIR laser for different irradiation cycles. After 
irradiated for 3 min (1 cycle), the cell/scaffold constructs were cooled down to the room temperature and 
then were irradiated for another 3 min (2 cycles). This process was repeated for 3 times. The cell viability 
was evaluated using WST-1 assay after each irradiation cycle. Every three samples were used for the 
measurement to calculate the average and standard deviation. 
Live/dead staining with a cellstain live-dead double staining kit was used to confirm the live and dead 
cells in the scaffolds after NIR irradiation for different cycles or without NIR irradiation. The cell/scaffold 
constructs were washed twice with PBS and incubated in serum-free EMEM medium containing calcein AM 
and propidium iodide (PI) for 15 min. And then, the samples were observed under a fluorescent microscope 
(Olympus, Japan). 
2.3.9 Statistical analysis  
All of the data were presented as mean ± standard deviation (SD). Statistical analysis was performed 
using a one-way analysis of variance with Tukey’s post hoc test for multiple comparisons. A value of p < 
0.05 was considered to indicate a statistically significant difference. 
 
2.4 Results and discussion 
2.4.1 Morphology of Fe3O4 nanoparticles  
The morphology and size distribution of the as-prepared Fe3O4 nanoparticles are shown in Fig. 2.1 (a-b). 
The Fe3O4 nanoparticles possessed a spherical or quasi-spherical shape and a shape size distribution. A small 
amount of nanoparticles aggregated which might be caused by the magnetic assembly. The average diameter 
of single Fe3O4 nanoparticles was 18.4 ± 2.5 nm. The hydrodynamic size of the Fe3O4 nanoparticles dispersed 
in water was measured to be 164.1 ± 2.5 nm by dynamic light scattering (DLS). The hydrodynamic size of 
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the nanoparticles was much larger than that measured from TEM. This may be due to the aggregation of 
Fe3O4 nanoparticles in water. The Fe3O4 nanoparticles would easily assemble in aqueous solution 
 
 
Fig. 2.1. (a) TEM image of Fe3O4 nanoparticles. (b) Diameter histogram of Fe3O4 nanoparticles measured 
from TEM images. (c) Hydrodynamic size of Fe3O4 nanoparticles measured by DLS. 
 
2.4.2 Characterization of Gel and the Gel/Fe3O4 composite scaffolds  
Fig.2.2 shows the gross appearance and morphology of Gel scaffolds and Gel/Fe3O4 composite scaffolds. 
The color of the composite scaffolds turned from white into brown after incorporation of Fe3O4 nanoparticles. 
With the increased amount of Fe3O4 nanoparticles, the color became darker, suggesting an enhanced light 
absorption property. SEM images showed that the pore structure of the scaffolds with different amount of 
Fe3O4 nanoparticles did not show obvious difference. All the scaffolds prepared with ice particulates had 
spherical large pores. The large pores were distributed homogeneously throughout the scaffolds and their 
size was almost equal to the size of added ice particulates (Table 2.1). Moreover, during the pre-freezing 
process (-20 
o
C, 12 h), many small ice crystals were in-situ formed around the added large ice particulates 
and they could also serve as porogen, thus inducing the formation of many small pores between the spherical 
large pores (Fig. 2.2(b)). The small pores having average size around 100 µm (Table 2.1) made the scaffolds 
well interconnected and the porosity of all the scaffolds was higher than 98.5 % (Table 2.1). The high 
porosity and good interconnectivity should be beneficial for the penetration and spatial distribution of cells. 
The images at a high magnification showed that the pore walls of Gel scaffold possessed a smooth surface 
(Fig. 2.2(c)). The surface of the pore walls in Gel/Fe3O4 composite scaffolds became rough and the Fe3O4 
nanoparticles were shown to be evenly distributed on the pore walls. As the amount of Fe3O4 nanoparticles 
increased, Fe3O4 nanoparticles on the pore walls became more evident. The size of the Fe3O4 nanoparticles on 
pore walls was about 200 nm, which was much larger than that of Fe3O4 nanoparticles size measured from 
TEM but close to the hydrodynamic size. The result indicated the Fe3O4 nanoparticles were partially 
aggregated during scaffold preparation. 
The XRD patterns of Gel scaffolds and Gel/Fe3O4 composite scaffolds are shown in Fig. 2.3. As a 
reference, the pure Fe3O4 nanoparticles were also analyzed, in which typical peaks of Fe3O4 (JCPDS 19-0629) 
were shown.
48
 Gel scaffolds exhibited a broad peak in the range of 15 ~ 30°, which was a typical 
characteristic for pure gelatin.
49, 50
 From the XRD patterns of all the Gel/Fe3O4 scaffolds, the characteristic 
peaks of Fe3O4 were detected. The results confirmed the presence of Fe3O4 in the Gel/Fe3O4 composite 
scaffolds. 
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Fig. 2.2. (a) Gross appearance and (b) SEM images of Gel scaffolds and Gel/Fe3O4 composite scaffolds. (c) 
SEM images of the corresponding scaffolds showing the morphology of pore walls at a high magnification. 
 
Table 2.1. Pore size (large pores and small pores) and porosity of Gel and Gel/Fe3O4 composite scaffolds. 
Data represent mean ± SD. 
 
Sample Gel Gel/Fe3O4-1 Gel/Fe3O4-5 Gel/Fe3O4-10 Gel/Fe3O4-15 
Large pores 
(μm) 
458 ± 41 448 ± 36 441 ± 34 455 ± 27 453 ± 31 
Small pores 
(μm) 
107 ± 16 95 ± 14 99 ± 14 99 ± 13 101 ± 14 
Porosity (%) 98.7 ± 0.5 98.9 ± 0.6 99.1 ± 0.2 98.7 ± 0.2 98.5 ± 0.3 
 
TGA analysis was used to determine the quantity of Fe3O4 in the scaffolds. As shown in Fig. 2.4, the 
Fe3O4 nanoparticles showed a slight weight loss, which was probably due to the thermal-degradation of the 
the surface coated citrate on the nanoparticles that was remained during preparation of nanoparticles. The 
typical single mass-loss step of Gel and Gel/Fe3O4 scaffolds was located at 300 ~ 500 
o
C. It was attributed to 
the degradation of Gel fibers including depolymerization, dehydration and decomposition followed by 
formation of a charred residue.
50
 Based on the residual mass of the composite scaffolds, the amount of Fe3O4 
in the Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 porous scaffolds was 0.8 ± 0.5%, 6.8 ± 
0.8%, 13.7 ± 0.6% and 18.7 ± 1.3%, respectively. The amount of incorporated Fe3O4 nanoparticles was 
almost the same as the added amount during scaffold preparation. 
 
The UV-Vis absorption spectra were measured to investigate the absorption properties of the Gel 
scaffolds and Gel/Fe3O4 composite scaffolds in near-infrared (NIR) region (Fig. 2.5). The pure Gel scaffolds 
presented almost no absorption of NIR light. In contrast, after incorporating with Fe3O4, all the Gel/Fe3O4 
scaffolds showed a broad and continuous absorption spectrum in the NIR region, which was well consistent 
with previous reports.
11, 12
 Furthermore, the NIR absorption increased with the increasing amount of Fe3O4 
nanoparticles. The obvious NIR absorption of Gel/Fe3O4 composite scaffolds suggested their potential for 
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photothermal therapy applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. XRD patterns of the Gel, Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 composite 
scaffolds. Pure Fe3O4 nanoparticles were also analysed for comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. TG analysis of the Gel, Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 composite 
scaffolds. Pure Fe3O4 nanoparticles were also analysed for comparison. 
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Fig. 2.5. UV-Vis absorption spectra of the Gel, Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 
composite scaffolds. 
2.4.3 Photothermal conversion efficiency of the Gel/Fe3O4 composite scaffolds  
The photothermal conversion effect was studied by exposing scaffolds (filled with culture medium) to an 
805 nm laser (Fig. 2.6). The temperature of the Gel/Fe3O4 composite scaffolds increased rapidly under the 
laser irradiation. In contrast, the pure Gel scaffolds exhibited slight heating under the identical condition. 
Moreover, higher content of Fe3O4 nanoparticles in the composite scaffolds resulted in higher temperature 
rise (Fig. 2.6a). The temperature increase was 9.3 ± 0.3 
o
C, 18.4 ± 0.3 
o
C, 21.2 ± 0.9 
o
C and 26.1 ± 0.4 
o
C for  
Fig. 2.6. (a) Temperature-time curve for the Gel scaffolds and Gel/Fe3O4 composite scaffolds under NIR 
irradiation, (b) Elevated temperature profile of Gel/Fe3O4-15 composite scaffolds over three laser on-off 
cycles. 
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Gel/Fe3O4-1, Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 scaffolds, respectively. To examine the 
photostability of Gel/Fe3O4 composite scaffolds, Gel/Fe3O4-15 scaffolds were irradiated by laser for different 
cycles. As shown in Fig. 2.6b, no significant change in the elevated temperature profiles was observed 
throughout the three cycles of NIR laser irradiation, which suggested that the Gel/Fe3O4-15 scaffolds 
possessed a good photostability. The results suggested that the Gel/Fe3O4 porous scaffolds could rapidly and 
efficiently convert NIR energy into thermal energy. More importantly, a significant advantage of these 
scaffolds for cancer therapy was their capability for repeatable photo-heating treatment without losing the 
heating efficiency.  
2.4.4 Cell adhesion and proliferation in the Gel and Gel/Fe3O4 composite scaffolds  
 The biocompatibility of Gel/Fe3O4 scaffolds was evaluated by examination of adhesion and 
proliferation of HeLa cells in the scaffolds. HeLa cells were seeded and cultured in the Gel and Gel/Fe3O4 
scaffolds. After culture for 1 d, cell adhesion and spatial distribution were evaluated by SEM. After cultured  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7. (a) SEM images of Gel and Gel/Fe3O4 scaffolds after cell culture of 1 d. (b) DNA quantification of 
Gel and Gel/Fe3O4 scaffolds after cell culture of 1, 3 and 7 d. The data are presented as mean ± SD values. 
N.S., no significant difference, *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
for 1, 3, and 7 d, the cell/scaffold constructs were used for quantification of DNA amount. SEM observation 
showed that the cells had a homogeneous distribution and well adhered on the pore walls of the Gel and 
 (b) 
(a) 
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Gel/Fe3O4 composite scaffolds as shown in Fig. 2.7a. There was no difference in cell adhesion among the 
Gel scaffolds and Gel/Fe3O4 composite scaffolds. The DNA amount in all the scaffolds significantly 
increased with culture time (Fig. 2.7b). There was no significant difference of DNA amount among the 
scaffolds. The results indicated that the cells could adhere and proliferate in all the scaffolds. Incorporation 
of Fe3O4 nanoparticles did not influence cell adhesion and proliferation, suggesting good biocompatibility of 
the Gel/Fe3O4 composite scaffolds. The Fe3O4 nanoparticles were embedded in the gelatin matrices of the 
composite scaffolds and should not directly interact with the cells. The cells adhered in the scaffolds through 
interaction with gelatin matrices that has been reported to have good biocompatibility.
51, 52
 
2.4.5 In vitro photothermal ablation of HeLa cells 
The localized photothermal therapeutic effect of Gel/Fe3O4 composite scaffolds on HeLa cells was 
evaluated by exposing the cell/scaffold constructs to NIR laser for 3 min (1 cycle). WST-1 was used to 
determine the cell viability (Fig. 2.8). Without laser irradiation, the cell viability in Gel and Gel/Fe3O4 
scaffolds did not show obvious difference. When the Gel scaffolds were exposed to the NIR laser, as a 
control group, the cell viability decreased a little with no significant difference from the case without laser 
irradiation. The results indicated that the Gel scaffolds had no photothermal therapy capability for cancer 
cells and the laser irradiation only had very small influence on cell viability. However, a significant decrease 
of cell viability was observed in all the Gel/Fe3O4 composite scaffolds after laser irradiation for 3 min. 
Moreover, the cell viability decrease was dependent on the amount of Fe3O4 nanoparticles in the composite 
scaffolds. In particular, the cell viability in Gel/Fe3O4-15 decreased to almost 0% after laser irradiation. It 
meant almost all the cancer cells were killed, suggesting a very high photothermal therapy capability of the 
Gel/Fe3O4-15 scaffolds. Higher amount of Fe3O4 nanoparticles in the composite scaffolds had a higher 
killing effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. Cell viability of HeLa cells in the Gel scaffolds and Gel/Fe3O4 composite scaffolds without or with 
3 min laser irradiation (one irradiation cycle). The data are presented as mean ± SD values. N.S., no 
significant difference, *p < 0.05, **p < 0.01 and ***p < 0.001. 
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In clinical application, one of the problems is recurrence of tumor. The repeating photothermal 
treatment should provide an efficient solution to this issue. However, conventional nanoparticle 
injection-based photothermal technology is hardly to achieve this goal because of the easy leakage of 
nanoparticles from tumor sites. Herein, we supposed the porous Gel/Fe3O4 composite scaffolds could serve 
as a localized photothermal agent, thus providing ideal platform for repeating photothermal therapy. In order 
to confirm this hypothesis, the cell cultured Gel/Fe3O4 scaffolds were exposed to the NIR laser for different 
repeated heating cycles and the cell viability after each cycle was measured (Fig. 2.9). Even after 3 cycles of 
laser irradiation, the cell viability in the Gel scaffolds was still as high as 85.6 ± 1.6%. However, when the 
Gel/Fe3O4 composite scaffolds were exposed to the NIR laser for different irradiation cycles, the cell viability 
decreased significantly, especially for the Gel/Fe3O4-5, Gel/Fe3O4-10 and Gel/Fe3O4-15 composite scaffolds. 
Almost all of the cells in Gel/Fe3O4-15 were killed just after one cycle irradiation. Moreover, the cell 
viability in Gel/Fe3O4-5 composite scaffolds after one irradiation cycle was reduced to 67.8 ± 7.2%, and 
further reduced to 54.9 ± 4.5% and 35.6 ± 9.3% after two and three irradiation cycles, respectively. The 
photothermal killing effect during repeating irradiation increased with the amount of incorporated Fe3O4 
nanoparticles. Particularly, almost all of the cancer cells in Gel/Fe3O4-10 scaffold were shown to be killed 
after three cycle of irradiation. These results indicated that the repeated laser irradiation could lead to an 
enhanced photothermal killing effect on cancer cells in the Gel/Fe3O4 composite scaffolds, suggesting the 
composite scaffolds might offer a good therapy strategy to address the recurrence of tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.9. Cell viability of HeLa cells in the scaffolds with repeating laser irradiation for different cycles. The 
data are presented as mean ± SD values. 
 
Live/dead staining of cells cultured in the Gel and Gel/Fe3O4 scaffolds with and without laser irradiation 
was conducted to visualize the photothermal ablation of cancer cells. As shown in the Fig. 2.10, most of the 
cells were alive (indicated by green fluorescence) in the Gel scaffolds even after 3 times of laser irradiation. 
As for the Gel/Fe3O4 composite scaffolds, few dead cells (indicated by red fluorescence) were observed 
without laser irradiation treatment. However, upon exposure to the NIR laser, numerous HeLa cells were 
dead. More dead cells were observed when the amount of Fe3O4 nanoparticles in composite scaffolds and 
laser irradiation cycle increased. For the Gel/Fe3O4-15 composite scaffold, one laser irradiation cycle was 
enough to kill all of the Hela cells, indicating their high photothermal cancer ablation efficiency. These 
live/dead staining results were well consistent with the above WST-1 results.  
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Fig. 2.10. Live/Dead staining of HeLa cells in the Gel scaffolds and Gel/Fe3O4 composite scaffolds without 
or with laser irradiation for different cycles. 
 
The results indicated that the Gel/Fe3O4 composite scaffolds could kill cancer cells efficiently through 
NIR laser irradiation. The killing efficiency of the Gel/Fe3O4 scaffolds could be improved by repeated 
photothermal treatment. The killing effect of the composite scaffolds should be due to the raised temperate 
generated from the photothermal conversion during NIR laser irradiation. Higher content of Fe3O4 
nanoparticles in the composite scaffolds induced higher temperature rise and therefore showed higher 
photothermal ablation effect. The increased capacity of photothermal ablation of the composite scaffolds 
with repeated laser irradiation should be due to the big increase of temperature in the composite scaffolds 
during repeated NIR laser irradiation. On the other hand, Fe3O4 nanoparticles in the scaffolds could be 
gradually degraded and Fe
3+
 ions should be released. Fe
3+
 ions have been reported to have good effects on 
cell responses.
38, 42
 Wu et al. have reported that the released Fe
3+
 ion can enhance bone-related gene 
expression and promote osteogenic differentiation of rBMSCs.
38
 Besides cancer cell ablation effect, the 
scaffolds should also have the capacity to stimulate tissue regeneration. 
2.5 Conclusions 
In summary, Gel/Fe3O4 composite scaffolds with controlled pore structures were prepared by 
incorporating Fe3O4 nanoparticles in the Gel porous scaffolds using ice particulates as a porogen material. 
The Gel/Fe3O4 composite scaffolds could absorb the NIR light and convert it to heat to elevate the local 
temperature efficiently. In vitro studies demonstrated that the Gel/Fe3O4 composite scaffolds had good 
biocompatibility and showed excellent photothermal ablation of cancer cells. All the cancer cells in the 
Gel/Fe3O4-15 composite scaffold having a high content of Fe3O4 nanoparticles could be killed after one cycle 
of laser irradiation. The Gel/Fe3O4 composite also showed the repeated local heating ablation of cancer cells 
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and repeated irradiation enhanced photothermal ablation effect. All of results indicated that Gel/Fe3O4 
composite scaffolds should be useful for photothermal therapy of cancer. 
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3.1 Summary 
Scaffolds have been explored as a useful carrier to deliver efficient photothermal conversion agents for 
localized photothermal therapy applications because of the limitations of free nanoparticles. However, cell 
capture by porous structures cannot discriminate cancer cells and normal cells. In this study, folic acid (FA) 
as a typical targeting ligand for cancer cells was introduced in the porous Gel/Fe3O4 scaffolds. Poly-L-lysine 
(PLL) was mixed with gelatin to increase amino side groups for FA incorporation. By changing PLL amount, 
the number of free amino groups in the composite scaffolds could be controlled. After reaction with activated 
FA, Gel/Fe3O4-FA composite scaffolds with different FA incorporation amount were prepared. Cell culture 
results showed that the Gel/Fe3O4-FA scaffolds could efficiently capture folate-positive cervical cancer cells 
(HeLa) compared with pure Gel scaffold within 30 min incubation. The capture efficiency increased with the 
increase of FA amount in the scaffolds. Furthermore, the Gel/Fe3O4-FA composite scaffold could efficiently 
kill cancer cells. Cancer cells in the composite scaffolds were killed during NIR laser irradiation. The results 
indicated that the multifunctional Gel/Fe3O4-FA porous scaffolds had good cancer cell capture ability and 
excellent cancer cells ablation efficacy, which may provide useful information for the design of 
multifunctional scaffolds with cancer cell capture capacity and photothermal ablation ability. 
3.2 Introduction 
As a promising strategy for malignant tumor treatment, photothermal therapy (PTT) has received 
intensive attention. PTT uses photothermal conversion agents to convert near infrared (NIR) light into heat to 
damage and kill cancer cells.
1, 2
 
3, 4
 Because of the small size and high photothermal conversion efficiency of 
nanomaterials, they have attracted great interest for PTT.
5-10
 Iron oxide (Fe3O4) nanoparticles have been 
widely investigated as conversion agents for PTT application due to their excellent photothermal conversion 
efficiency and non-invasive manipulation ability.
11-15
 However the poor targeting specificity and easy 
diffusion of free nanoparticles still restrict their broad application in clinic.
16-19
 
Recently, porous scaffold have been used as an effective carrier for localized delivery of photothermal 
Chapter 3 
46 
 
conversion agents.
20-25
 The scaffolds possess photothermal effect and can elevate local temperature quickly 
during NIR laser irradiation. Using photothermal scaffolds for PTT applications have some advantages 
comparing to free nanoparticles. One of main advantages of photothermal scaffolds is that they can be 
directly implanted into the tumor site.
26, 27
 Therefore, the immobilized photothermal conversion agents can be 
efficiently delivered and localized to the tumor site, which should be beneficial to achieving high local 
heating effect. More importantly, because the photothermal conversion agents are immobilized on the pore 
surfaces of the scaffold or embedded in the scaffold matrix, they can be easily retained at the tumor site for a 
long period and can been repeatedly used without leakage and decrement of heating efficiency.
28, 29
 
Furthermore, after tumor ablation, the porous scaffolds can also support penetration of healthy cells and 
promote regeneration of healthy tissue, which contributes to the subsequent tissue recovery and 
regeneration.
30-32
 However, although the photothermal scaffolds can accommodate various cells and have 
excellent photothermal efficiency, they cannot specifically or selectively capture and kill cancer cells. 
Therefore, it is highly desirable to increase the capture ability of cancer cells in porous scaffolds while 
minimize their damage to healthy cells. 
In this study, folic acid (FA), as a cancer cells recognition ligand,
33-38
 was introduced in the porous 
gelatin/iron oxide (Gel/Fe3O4) composite scaffolds. To increase the amount of FA in the scaffolds with a 
controllable manner, poly-L-lysine (PLL), was incorporated in gelatin (Gel) porous scaffolds to increase free 
amino side groups in the scaffolds for binding with FA. The Gel/Fe3O4-FA composite scaffolds possessed 
strong absorption in NIR region and the temperature could be quickly elevated during laser irradiation. 
Folate-positive cancer cells (HeLa) could be efficiently captured by the Gel/Fe3O4-FA composite scaffolds 
and the capture efficiency could be enhanced by the increasing of FA amount in the scaffolds. Furthermore, 
cancer cells in the Gel/Fe3O4-FA composite scaffold could be efficiently killed during laser irradiation. 
3.3 Materials and methods 
3.3.1 Materials 
Iron (III) chloride hexahydrate (FeCl3•6H2O, 97.0%), sodium sulfite (Na2SO3, 98.0%), 2-(Nmorpholino) 
ethanesulfonic acid (MES), Eagle’s minimum essential medium (EMEM), penicillin, streptomycin and 
trypsin/EDTA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Trisodium citrate dihydrate 
(C6H5Na3O7•2H2O,), 25 wt% ammonia solution, acetic acid, ethanol (99.5%), folic acid (FA), dimethyl 
sulfoxide (DMSO), glysine (99.0%), 6 mol/L hydrochloric acid (HCl), sodium hydroxide (NaOH, 96.0%) 
and N-hydroxysuccinimide (NHS) were purchased from Wako Pure Industries, Ltd (Tokyo, Japan). Porcine 
derived gelatin was provided by Nitta Gelatin (Osaka, Japan). Poly-L-lysine (PLL) and 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were purchased from Peptide Institute, Inc. (Osaka, 
Japan). WST-1 reagent was obtained from Roche Molecular Biochemicals (Mannheim, Germany). DAPI 
solution and live/dead double staining kit was purchased from Dojindo Laboratories (Kumamoto, Japan). 
Collagenese type I was purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA). All 
the chemicals and materials were used as received without further purification. The water in all experiments 
was purified using a Q-POD Milli-Q water purification system (Millipore Corp., Billerica, MA, USA) with a 
resistivity of 18.2 MΩ•cm.  
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3.3.2 Synthesis of Fe3O4 nanoparticles 
Citrate-stabilized Fe3O4 nanoparticles were synthesized according to a previously reported method.
39
 
Briefly, 20.0 mL Na2SO3 aqueous solution (20.0 mg/mL) was mixed with 40.0 mL FeCl3•6H2O aqueous 
solution (65.0 mg/mL) under nitrogen atmosphere protection. After mixing for 10 min, the mixture solution 
was put into a 75 
o
C water bath, followed by the addition of 4.0 mL ammonia solution (25 wt%) and 10 mL 
citrate solution (0.1 g/mL). After reaction for 40 min, the whole set was transferred on a magnetic stirrer at 
room temperature for more than 1.5 h to cool down solution and then the formed Fe3O4 nanoparticles were 
collected by magnetic separation, washed four times with MilliQ water and finally re-suspended in water and 
stored at 4 
o
C for further use. 
3.3.3 Preparation of PLL-incorporated porous Gel/Fe3O4 composite scaffolds 
PLL-incorporated porous Gel/Fe3O4 composite scaffolds were prepared by an ice particulates templating 
method according to a previously reported method with some modification.
40, 41
 Briefly, a Gel solution (95.0 
mg/mL) was firstly prepared by dissolving Gel into an acetic acid solution. An appropriate amount PLL (43.6 
mg, 60.9 mg, 95.4 mg and 164.5 mg) was dissolved in 4.2 mL water. And then 4.2 mL PLL solution was 
added into 5.0 mL Gel solution during magnetic stirring. After that, 970.0 μL Fe3O4 nanoparticles suspension 
solution (38.2 mg/mL) was added into the mixture solution dropwise and sonicated at room temperature for 
30 min. The mixture suspension solution was put at -4 
o
C for 40 min for temperature balance.  
Ice particulates were prepared by spraying pure water into liquid nitrogen.
42, 43
 The ice particulates with 
diameters in a range of 425 ~ 500 µm were obtained by sieving the prepared ice particulates at -15 
o
C with 
two sieves having average mesh sizes of 425 and 500 µm. And then the ice particulates were transferred into 
a cooled glass bottle and kept at -5 
o
C for 2 h for temperature balance. After 2 h temperature balance, the ice 
particulates were mixed thoroughly with the aforementioned cooled mixture suspension solution at a 
weight/volume ratio of 7 : 3 (g/mL) at -5 
o
C. The mixture of solution and ice particulates was poured into a 
cooled silicone mold and the entire set was first put into -20 
o
C low temperature chamber for 12 h and then 
transferred to -80 
o
C freezer for 4 h for further freezing. Finally, the frozen construct was freeze-dried for 3 d 
under a vacuum of less than 5 Pa for 24 h by using a freeze dryer (FDU-2200, Tokyo Rikakikai Co., Ltd.). 
After freeze-drying, the scaffolds were cut into thin slices and washed with ethanol (99.5%) for 10 times 
to remove residual acetic acid. After washing with ethanol, the composite scaffolds were cross-linked with 
EDC and NHS ethanol/water solution. Three mixture solvents with a decreasing ethanol concentration 
(ethanol/water = 95/5, 90/10, 85/15, v/v) were used to prepare the crosslinking solutions, which contained 50 
mM EDC, 20 mM NHS and 0.1% (wt/v) MES. The composite scaffolds were crosslinked sequentially by the 
three crosslinking solutions at room temperature for every 8 h in each solution. After cross-linking, the 
composite scaffolds were rinsed with PBS for 3 times. The composite scaffolds were further treated with 0.1 
M glycine at room temperature for 6 h to block the un-reacted but activated carboxyl groups in the scaffolds. 
Finally, the scaffolds were thoroughly washed with water for more than 10 times and freeze-dried for 2 d to 
obtain PLL-incorporated porous Gel/Fe3O4 composite scaffolds. The PLL-incorporated porous Gel/Fe3O4 
composite scaffolds prepared from the weight feeding ratio of PLL to (PLL and Gel) of 8.4, 11.4, 16.7 and 
25.7% were referred as CS-1, CS-2, CS-3 and CS-4, respectively. The pure Gel and Gel/Fe3O4 scaffolds were 
also prepared as controls. The preparation procedure was the same as that of the CS scaffolds without adding 
of PLL and Fe3O4 (Gel scaffold) or without PLL (Gel/Fe3O4 scaffold). 
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3.3.4 Preparation of porous Gel/Fe3O4-FA composite scaffolds 
FA was linked to the composite scaffolds by using ECD/NHS technique.
44-46
 Firstly, FA (0.5 mmol) was 
dissolved in 2.5 mL DMSO. And then EDC (1.0 mmol) and NHS (1.0 mmol) were added into the FA 
solution under stirring for 3 h. After activation, 2.5 mL FA/DMSO solution was added in 47.5 mL PBS 
solution (FA/DMSO/PBS). Subsequently the Gel/Fe3O4 scaffolds that were prepared as above mentioned 
without blocking with glycine were immersed in the FA/DMSO/PBS solution to react for 1 d. The ratio of 
feeding FA amount to the free amino groups in the scaffolds was set to 3 : 1. After reaction, the Gel/Fe3O4-FA 
scaffolds were washed with DMSO/PBS for 3 times, PBS for 3 times, MilliQ water for 3 times and then 
further treated with 0.1 M glycine for 6 h. Finally, the scaffolds were thoroughly washed with water for more 
than 10 times and freeze-dried for 2 d to obtain the final Gel/Fe3O4-FA composite scaffolds. The 
Gel/Fe3O4-FA composite scaffolds prepared from CS-1, CS-2, CS-3 and CS-4 were referred as CS-FA1, 
CS-FA2, CS-FA3 and CS-FA4, respectively. 
3.3.5 Characterization of Fe3O4 nanoparticles and scaffolds 
Morphology of the prepared Fe3O4 nanoparticles was investigated by transmission electron microscopy 
(TEM, JEOL 2011F, Japan). Dynamic light scattering (DLS) was used to measure the hydrodynamic size of 
the Fe3O4 nanoparticles. The morphology of Gel scaffolds and Gel/Fe3O4-FA composite scaffolds were 
observed by a scanning electron microscope (SEM, Hitachi S-4800, Japan). UV-visible absorption spectra of 
the solid phase scaffolds were recorded using a UV-2600 UV-visible spectrophotometer (Shimadzu Corp., 
Japan).  
3.3.6 Photothermal effect of the Gel/Fe3O4-FA composite scaffolds  
Photothermal effect of the Gel/Fe3O4-FA composite scaffolds with different FA grafting density was 
determined by exposing the scaffolds (5 × 3 × 1 mm) filled with 20 μL culture medium to a NIR laser (805 
nm, Thorlabs Inc., USA) with a power density of 1.6 W cm
-2
 for 180 s. During laser irradiation, a digital 
thermometer (AS ONE Corp., Japan) was used to measure the temperature of the samples every 10 s. Pure 
Gel scaffold was also exposed for 180 s as a control. Every three samples were used to calculate the average 
and standard deviation. 
3.3.7 Quantification of FA amount in Gel/Fe3O4-FA composite scaffolds 
UV-Vis absorbance was used to quantify the FA amount in the Gel/Fe3O4-FA composite scaffolds. 
Firstly, a small piece (17 × 11 × 1 mm) of Gel/Fe3O4-FA composite scaffold was dissolved in 2 mL HCl 
solution (6 M) for 6 h. In order to exclude the effect of Fe
3+
 ion, 6 M NaOH was added into above solution 
and adjusted pH of the solution above 13. And then the mixture solution was centrifuged at 9500 rpm for 10 
min. Finally, the supernant was taken out to measure the absorbance at FA specific absorption peak of 365 
nm by a V-660 UV-Vis spectrophotometer (Jasco Corp., Tokyo, Japan). Every three samples were used to 
calculate the average and standard deviation. 
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3.3.8 Cancer cell capture experiment 
A folate receptor-positive cell type, human cervical carcinoma cell line (HeLa cells), was used to 
evaluate the cell capture ability of Gel/Fe3O4-FA composite scaffolds. HeLa cells were seeded in 75 cm
2
 
tissue culture flasks and cultured in a regular EMEM medium supplemented with 10% FBS, penicillin (100 
U mL
-1) and streptomycin (100 μg mL-1) in 5% CO2 incubator at 37 
o
C in a humidified environment. The 
cells were subcultured using a 0.05% trypsin-EDTA solution after reaching confluence. The subcultured 
HeLa cells were collected by centrifugation and re-suspended in serum-free EMEM medium to a 
concentration of 1 × 10
6
/mL for cell seeding. 
Before cell seeding, the Gel and Gel/Fe3O4 scaffolds, CS scaffolds and CS-FA scaffolds were cut into 
discs, sterilized with 70% ethanol, washed with water for 5 times and immersed into serum-free medium at 
37 
o
C for 6 h. After removing the medium by using a sterile tissue paper, 1 × 10
5
 HeLa cells were seeded into 
Gel scaffolds and Gel/Fe3O4-FA composite scaffolds. 
For cell capture experiment, scaffolds were cut to cylinder-shape discs with a diameter of 6 mm and a 
height of 1 mm. The scaffold discs were put into glass rings (Φ 6 × H 10 mm) that were placed in the wells 
of a 24-well polystyrene cell culture plate. The glass rings were used to protect medium and cell leakage 
during cell seeding. 100 μL cell suspension solution (1 × 106/mL) was added to the scaffolds and incubated 
for 30 min. After 30 min incubation, the scaffolds were washed thoroughly with PBS for 3 times to remove 
un-attached cells. Gel, Gel/Fe3O4, CS-1, CS-2, CS-3 and CS-4 were also conducted as controls. 
3.3.9 Counting of captured cell number and DAPI staining 
After being cultured for 30 min as above mentioned, the cell/scaffold constructs were washed 
thoroughly by PBS. And then the cell/scaffolds constructs were put into 0.5 mL collagenase type I solution 
(0.5% (wt/v)) to digest for 10 min under mechanical shaking. After 10 min digestion, cell/scaffolds 
constructs were taken out and put into another 0.5 mL collagenase type I solution (0.5% (wt/v)) to digest for 
another 10 min. This process was repeated for 6 times and all the collagenase type I digestion solutions were 
collected (3.0 mL) into a 15.0 mL tube. 3.0 mL culture medium was added into the 15-mL tubes to stop the 
digestion. After that, the mixture solution was centrifuged at 1100 rpm for 5 min. Finally, supernatant was 
discarded and the cell pellets were re-suspended in 1.0 mL solution for counting cell number. Every six 
samples were used to calculate the average and standard deviation. 
DAPI staining was conducted to stain the cells nuclei to visualize the captured cells in the scaffolds. 
After 30 min culture, the cell/scaffold constructs were washed thoroughly by PBS and fixed with 2.5% 
glutaraldehyde at room temperature for 2 h. And then the cell/scaffold constructs were washed with PBS for 
3 times. Cell nuclei were stained with 1000-fold diluted DAPI solution in PBS at room temperature for 8 min. 
After staining, cell/scaffold constructs were rinsed with PBS for 3 times and their fluorescence images were 
obtained by using a fluorescent microscope (Olympus, Japan). 
3.3.10 Cell viability and photothermal effect of composite scaffolds 
For cell viability and photothermal effect experiments, the scaffolds were cut into discs (5 × 3 × 1 mm). 
10.0 μL cell suspension containing 1 × 105 HeLa cells were seeded into each scaffold disc. After 5 h of 
incubation, the cell/scaffold constructs were transferred into 6-well plates and cultured in 5.0 mL serum 
medium in 5% CO2 incubator at 37 
o
C. After cultured for 1 d, the cell/scaffold constructs were separated into 
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two different groups (without or with laser irradiation). For laser irradiation group, the cell/scaffold 
constructs were exposed to an NIR laser of 805 nm for 180 s. For no laser irradiation group, the cell/scaffold 
constructs were taken out from the incubator and put at room temperature for 180 s. After the treatments, the 
cell/scaffold constructs were cultured in serum medium for another 3 h. After that, cell viability was 
determined by WST-1 assay. The absorbance at 440 nm was measured by a microplate reader (Benchmark 
Plus, Bio-Rad, Hercules, CA, USA). The cell viability was normalized with the viability data of cells 
cultured in the Gel scaffolds. Every three samples were used for the measurement to calculate the average 
and standard deviation. 
3.3.11 Statistical analysis 
All of the data were presented as mean ± standard deviation (SD). Statistical analysis was performed 
using a one-way analysis of variance with Tukey’s post hoc test for multiple comparisons. A value of p < 
0.05 was considered to indicate a statistically significant diﬀerence. The data were indicated with (*) for p < 
0.05, (**) for p < 0.01 and (***) for p < 0.001, respectively. 
3.4 Results and discussion 
3.4.1 Morphology of citrate-stabilized Fe3O4 nanoparticles 
The Fe3O4 nanoparticles had spherical or quasi-spherical morphology as shown in Figure 3.1a. DLS 
analysis showed that the Fe3O4 nanoparticles dispersed in water had a single peak distribution (Figure 3.1b). 
Their hydrodynamic size was 123.1 ± 1.3 nm, which was much larger than the size measured from TEM 
images. This should be due to the partial aggregation of Fe3O4 nanoparticles in water. The partial aggregation 
in water should not affect the distribution of Fe3O4 nanoparticles in gelatin aqueous solution during scaffold 
preparation. 
 
Fig. 3.1. TEM image of Fe3O4 nanoparticles (a). Hydrodynamic size of Fe3O4 nanoparticles measured by 
DLS (b). 
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3.4.2 Pore structure and surface morphology of Gel/Fe3O4-FA composite scaffolds 
The Gel/Fe3O4-FA composite scaffolds were prepared by using ice particulates as a porogen material to 
control large pore structures. SEM observation showed that Gel and Gel/Fe3O4-FA composite scaffolds with 
different amount of FA had similar pore structures (Figure 3.2). Their pore structures and pore surfaces did 
not show obvious change. All the scaffolds possessed well controlled and interconnected pore structures 
consisting spherical large pores and interconnected small pores. The large pores were formed by the added 
ice particulates with controlled size (425 ~ 500 μm). The small pores should be due to the formed new ice 
crystals during freezing process. The well interconnected pore structure should be beneficial for cell 
penetration and adhesion into the scaffolds, resulting in a homogenous cell distribution throughout the 
scaffolds. High magnification SEM images showed the Gel/Fe3O4-FA composite scaffolds had rougher pore 
surfaces than did the pure Gel scaffolds. The size of Fe3O4 nanoparticles on the pore surfaces was larger than 
their size in TEM images but close to their hydrodynamic size. The results indicated that the Fe3O4 
nanoparticles were partially aggregated in the Gel/Fe3O4-FA composite scaffolds. 
 
 
Fig. 3.2. SEM images of Gel, CS-FA1, CS-FA2, CS-FA3 and CS-FA4 scaffolds at a low magnification and 
morphology of pore surfaces at a high magnification. 
 
3.4.3 UV absorption and photothermal conversion effect of Gel/Fe3O4-FA composite scaffolds 
UV-Vis spectra were measured to evaluate the absorption properties of the Gel scaffolds and 
Gel/Fe3O4-FA composite scaffolds (Figure 3.3). Gel scaffolds showed no absorption at NIR wavelength (700 
~ 1100 nm). However the Gel/Fe3O4 composite scaffolds showed strong absorption at the NIR wavelength. 
The strong absorption of Gel/Fe3O4 composite scaffolds was due to the incorporation of Fe3O4 nanoparticles. 
Introduction of PLL and FA had no influence on the absorption of the composite scaffolds. 
Photothermal conversion effect was investigated by irradiating Gel and Gel/Fe3O4-FA composite 
scaffolds with an 805 nm laser (Figure 3.4). The temperature of Gel scaffolds only slightly increased during 
laser irradiation. In contrast, the temperature of Gel/Fe3O4-FA composite scaffolds increased rapidly with 
laser irradiation. The temperature increase was 24.3 ± 0.6 
o
C, 24.2 ± 0.3 
o
C, 24.1 ± 0.9 
o
C and 23.7 ± 0.4 
o
C 
for CS-FA1, CS-FA2, CS-FA3 and CS-FA4 scaffolds, respectively. The photothermal conversion effect was 
ascribed to the strong NIR absorption of Fe3O4 nanoparticles in the composite scaffolds. Because the same 
amount of Fe3O4 nanoparticles was incorporated in all the composite scaffolds, temperature change of all the 
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Gel/Fe3O4-FA composite scaffolds with different FA grafting density was almost the same. 
 
 
 
Fig. 3.3. UV spectra of Gel, CS-FA1, CS-FA2, CS-FA3 and CS-FA4 scaffolds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Temperature-heating time curves (b) of Gel, CS-FA1, CS-FA2, CS-FA3 and CS-FA4 scaffolds. 
 
3.4.4 FA amount in Gel/Fe3O4-FA composite scaffolds 
The amount of FA in each composite scaffold was measured by detecting FA absorbance of scaffold 
digestion solution after dissolving the scaffolds and removing iron ions from the digestion solution (Figure 
3.5). The typical absorption peaks of FA are located at 274 and 365 nm.
47, 48
 The spectra showed that the 
composite scaffolds without incorporation of FA had no absorption near 365 nm. However, after introducing 
FA, the absorption peaks near 274 and 365 nm appeared and the absorbance intensity of the Gel/Fe3O4-FA 
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composite scaffolds increased with the increasing of FA amount. A UV-Vis calibration curve for FA has been 
drawn according to the FA concentration versus the absorption value at 365 nm (Fig. 3.6). Based on the 
calibration curve, the FA amount in the Gel/Fe3O4-FA composite scaffolds was calculated to be 88.0 ± 9.0 μg, 
223.7 ± 22.6 μg, 325.3 ± 1.2 μg and 517.4 ± 129.7 μg for CS-FA1, CS-FA2, CS-FA3 and CS-FA4, 
respectively. According to the theoretical value of free amino groups in the composite scaffolds, the reaction 
efficiency was 30.8 ± 4.9%, 39.1 ± 2.2%, 30.6 ± 1.4% and 30.5 ± 3.8% for CS-FA1, CS-FA2, CS-FA3 and 
CS-FA4, respectively. The feed ratio of FA to free amino groups was kept at the same and therefore the 
reaction efficiency of FA to the free amino acid group was almost at the same level. The results indicated that 
the incorporated FA amount could be controlled by the free amino groups in the scaffolds, which could be 
regulated by the incorporated PLL amount in the scaffolds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. UV spectra of Gel, Gel/Fe3O4, CS-1, CS-2, CS-3 and CS-4, CS-FA1, CS-FA2, CS-FA3 and 
CS-FA4 scaffolds after dissolution in an alkaline solution and removal of iron ions. 
 
Fig. 3.6. UV spectra of FA solution with different FA concentration(a). Calibration curve of FA according to 
the FA concentration versus the absorption value at 365 nm (b). 
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3.4.5 Cancer cell capture and quantification 
HeLa cells were seeded and cultured in the Gel, Gel/Fe3O4 and Gel/Fe3O4-FA composite scaffolds for 30 
min. DAPI staining showed the distribution of captured HeLa cells in the scaffolds (Figure 3.7a). The cells 
were captured by the pore structures in the scaffolds. More cells were observed in the Gel/Fe3O4-FA 
composite scaffolds than were in the Gel and Gel/Fe3O4 composite scaffolds. Furthermore, the number of 
captured cells was counted (Figure 3.7b). There were some cells adhered in the Gel and Gel/Fe3O4 scaffolds. 
The cell adhesion cites such as RGD sequence in gelatin molecules could support cell adhesion. There was 
no significant difference between the cell number in Gel scaffold and Gel/Fe3O4 composite scaffolds. Due to 
the positive charge of PLL, introduction of PLL slightly enhanced cell adhesion. Introduction of FA in the 
scaffolds significantly increased the captured cell number. The captured cell number in Gel/Fe3O4-FA 
composite scaffolds was significantly higher than the captured cell number in Gel scaffold and Gel/Fe3O4 
scaffolds. Furthermore the captured cell number in Gel/Fe3O4-FA composite scaffolds increased with the 
increasing of FA amount until saturation. CS-4, CS-3 composite scaffolds possessed the same highest 
captured cell number, which indicated that the capture efficiency would not increase if the FA amount 
continued to increase after saturation. 
 
Fig. 3.7. DAPI staining (a) and quantified cell number (b) of the Gel, Gel/Fe3O4, CS-1, CS-2, CS-3, CS-4, 
CS-FA1, CS-FA2, CS-FA3 and CS-FA4 scaffolds after incubation with HeLa cells for 30 min. 
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3.4.6 In vitro photothermal ablation of cancer cells  
The killing effect of the composite scaffolds was confirmed by measuring cell viability without and with 
laser irradiation (Figure 3.8). Without laser irradiation, cell viability in Gel, CS-FA1 and CS-FA2 scaffolds 
showed no significant difference and all of them possessed quite high cell viability. However, the cell 
viability significantly decreased in CS-FA3 and further decreased in CS-FA4, which should be due to the 
high PLL amount in CS-FA3 and CS-FA4. PLL has been reported to have some cytotoxicity to the cells.
49, 50
 
To confirm cytotoxicity of introduced PLL in the composite scaffolds, cell viability of Gel, Gel/Fe3O4, CS-1, 
CS-2, CS-3 and CS-4 scaffolds was also measured and compared (Figure 3.9). The results showed that 
incorporation of Fe3O4 nanoparticles in the scaffolds did not cause obvious cytotoxicity. However cell 
viability decreased with the increasing PLL amount in the composite scaffolds. Therefore, too high PLL 
amount in the composite scaffolds was not desirable because of its cytotoxicity. After laser irradiation for 3 
min, most of the cells in the Gel/Fe3O4-FA composite scaffolds were dead. Cell viability in the CS-FA1, 
CS-FA2, CS-FA3 and CS-FA4 was 0.8 ± 0.4%, 1.2 ± 1.8%, 0.7 ± 1.2% and 1.2 ± 1.2%, respectively. 
However cell viability in Gel scaffold was not significantly different from that without laser irradiation. The 
results indicated that the Gel/Fe3O4-FA composite scaffolds possessed excellent cancer cell ablation ability. 
The well controlled pore structures of the composite scaffolds facilitated cell penetration and access to the 
pores of the scaffolds. The FA ligands on the pore surfaces of Gel/Fe3O4-FA composite scaffolds helped to 
effectively capture cancers when the cells entered the scaffolds. Fe3O4 nanoparticles in the Gel/Fe3O4-FA 
composite scaffolds could efficiently transfer the energy for laser irradiation to heat to kill the captured 
cancer cells. The multifunctional composite scaffolds should be useful for photothermal cancer therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8. Cell viability of HeLa cells in the Gel scaffolds and Gel/Fe3O4-FA composite scaffolds without or 
with 3 min laser irradiation. 
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Fig. 3.9. Cell viability of HeLa cells on Gel, Gel/Fe3O4, CS-1, CS-2, CS-3 and CS-4 without laser 
irradiation.  
 
3.5 Conclusions 
In summary, a multifunctional Gel/Fe3O4-FA composite scaffold for cancer cell capture and 
photothermal ablation was successfully prepared. The pore structures were controlled by using pre-prepared 
ice particulates. By adjusting the fed PLL amount, the number of free amino groups in the composite 
scaffolds could be easily modulated. The targeting ligand, FA, was immobilized in the Gel/Fe3O4 composite 
scaffolds by reaction with the free amino groups in the scaffolds to obtain Gel/Fe3O4-FA composite scaffold 
with different FA grafting density. The Gel/Fe3O4-FA composite scaffold could efficiently capture cancer 
cells and the captured cell number significantly increased with the increasing FA amount in the composite 
scaffolds. The composite scaffolds showed good photothermal conversion efficiency and could efficiently 
kill the cancer cell during NIR laser irradiation. The results should be important for the design and 
preparation of biomaterials and scaffolds for effective photothermal cancer therapy and tissue regeneration. 
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Composite scaffolds of gelatin and gold nanoparticles with tunable 
size and shape for photothermal cancer therapy 
 
 
 
 
4.1 Summary 
Photothermal therapy (PTT) has been extensively investigated as a promising strategy for cancer 
therapy. For successful application of this technique, various nanomaterials have been explored as 
photothermal conversion agents. Gold nanoparticles (AuNPs), especially Au nanorods and Au nanostars have 
received much attention for photothermal therapy because of their facile preparation and high photothermal 
conversion efficiency. Due to the limited accumulation and easy diffusion of free nanoparticles, 
incorporation of nanoparticles in scaffolds for direct implantation has been demonstrated as an attractive way 
for cancer therapy application. In this study, composite porous scaffolds of gelatin and AuNPs were prepared 
by introducing Au nanorods and nanostars with an average size around 35.0, 65.0 and 115.0 nm in gelatin 
scaffolds. The composite scaffolds were used for localized PTT application of cancer cells. Gel/AuNP 
composite scaffolds supported cell adhesion and showed good biocompatibility. Temperature in the 
composite scaffolds increased quickly upon NIR laser irradiation. The photothermal efficiency and cancer 
cell killing efficiency were dependent on the shape, size and amount of AuNPs in the composite scaffolds. 
The composite scaffold prepared with 65.0 nm Au nanorods showed the highest photothermal efficiency and 
cell killing efficiency. The results indicated the importance of shape and size modulation of AuNPs for 
photothermal therapy application.   
4.2 Introduction 
Cancer is one of the leading causes of death in the world.
1, 2
 Current cancer therapies still face some 
challenges such as cancer recurrence and side effects.
3-5
 Recently, photothermal therapy (PTT) has emerged 
as a novel approach for cancer therapy application. PTT is based on localized heating by utilizing the 
photothermal conversion agents to absorb near infrared (NIR, 700-1100 nm) light, thereby leading to the 
destruction of cancer cells.
6
 Nowadays, a variety of nanoscaled materials have been reported to be used as 
PTT agents such as magnetic nanoparticles (NPs),
7-9
 copper sulfide NPs,
10-12
 molybdenum sulfide 
nanosheets,
13-15
 carbon-based nanomaterials 
16-19
 and gold-based nanomaterials.
20-24
 Among them, gold 
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nanoparticles (AuNPs) have received increasing attention because of their facile preparation and good 
photothermal conversion properties. AuNPs with different size and shape can be easily prepared and their 
surface plasmon resonance (LSPR) peaks are tunable by altering their size and shape.
25, 26
 In addition, high 
photothermal conversion efficiency and good biocompatibility also make them as ideal photothermal 
conversion agents.
27-29
 However, the local and precise delivery of NPs to cancer sites still remains a great 
challenge. After injection of free NPs, accumulation of AuNPs in tumor sites is very limited and the 
accumulated NPs can easily diffuse because of their small size.
2, 30
 Therefore, developing other effective 
strategy for localized therapy is highly needed.  
Some recent studies have reported immobilization of PTT agents in three-dimensional scaffolds to 
prepare composite scaffolds for cancer therapy application.
31-34
 In such cases, the composite scaffolds can 
retain the PTT agents in tumor sites at a high amount for a long period, hence achieving repeated local 
heating without losing photothermal efficiency. 
30, 34, 35
 Therefore, in this study AuNPs were immobilized in 
gelatin (Gel) porous scaffolds to prepare Gel/AuNP composite scaffolds to increase localized photothermal 
therapy. Au nanorod (AuNR) and Au nanostar (AuNS) with different sizes were used to prepare the 
composite scaffolds because the shape and size of AuNPs may change their LSPR peaks and influence their 
photothermal efficiency. SEM and UV-Vis were used to investigate the morphology and LSPR peaks of 
Gel/AuNP composite scaffolds. The photothermal conversion efficiency and cancer cell killing efficiency of 
the Gel/AuNP composite scaffolds were determined by exposing the scaffolds to a NIR laser. The results 
showed that the local photothermal efficiency and cancer cell killing efficiency were highly dependent on the 
shape, size and amount of corresponding AuNPs. Compared with the other composite scaffolds, composite 
scaffolds immobilized with 65.0 nm AuNR exhibited the superior photothermal efficiency and cancer cell 
killing efficiency. The results not only highlighted the importance of shape and size modulation on AuNP for 
PTT application but also indicated the potential to use of this Gel/AuNP composite scaffold as an 
implantable material for tumor resection. They will provide guidance towards the design and application of 
efficient photothermal scaffolds for cancer therapy. 
4.3 Materials and methods 
4.3.1 Materials 
Hexadecyltrimethylammonium bromide (CTAB), ascorbic acid (AA), sodium borohydride (NaBH4), 
silver nitrate (AgNO3), 2-(nmorpholino) ethane sulfonic acid (MES), Eagle’s minimun essential medium 
(EMEM), penicillin, streptomycin, L-glutamine and trypsin/EDTA were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Hydrogen tetrachloroaurate tetrahydrate (HAuCl4·4H2O, 99.9%), hydrochloric acid, 
hydroquinone, trisodium citrate dihydrate (C6H5Na3O7·2H2O,), acetic acid (99.9%), ethanol (99.5%) and 
N-hydroxysuccinimide (NHS) were purchased from Wako Pure Industries, Ltd (Tokyo, Japan). Fetal bovine 
serum (FBS) was purchased from Funakoshi Industries (Tokyo, Japan). Porcine derived gelatin was provided 
by Nitta Gelatin (Osaka, Japan). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was purchased 
from Peptide Institute, Inc. (Osaka, Japan). WST-1 reagent was obtained from Roche Molecular 
Biochemicals (Mannheim, Germany). Cellstain live-dead double staining kit was purchased from Dojindo 
Laboratories (Kumamoto, Japan). All the chemicals and materials were used as received without further 
purification. The water in all experiments was purified using a Q-POD Milli-Q water purification system 
(Millipore Corp., Billerica, MA, USA) with a resistivity of 18.2 MΩ·cm. 
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4.3.2 Preparation of AuNPs with different size and shape 
AuNPs with different size (around 35.0 nm, 65.0 nm and 115.0 nm) and shape (AuNR and AuNS) were 
prepared according to a previous report.
36
 Briefly, AuNR35 (R35) and AuNR65 (R65) were synthesized by a 
seed-mediated growth method and the Au seed solution was prepared by a chemical reduction of HAuCl4 
with NaBH4 with CTAB as a stabilizer. The growth solution was prepared by adding 30 mL of 0.01 M 
HAuCl4, 12 mL of 1.0 M HCl, 1.32 mL or 6.6 mL of 10 mM AgNO3 and 4.8 mL of 0.1 M AA in 600 mL of 
0.1 M CTAB solution. 1.44 mL of the Au seed solution was added to the growth solution and the mixture 
solution was incubated at room temperature for 12 h. By varying the amount of AgNO3, AuNR with diﬀ erent 
length were formed. AuNR115 (R115) was synthesized by a facile one-pot method. In brief, 22.8 mL of 
HAuCl4 (0.01 M), 6 mL of AgNO3 (0.02 M) and 4.8 mL of hydroquinone (0.62 M) were sequentially added 
to 534 mL of CTAB solution (0.11 M) to yield a colorless solution. Subsequently, 378 μL of NaBH4 solution 
(0.5 M) was added and the resultant mixture was kept standing at 30 °C for 24 h. The obtained AuNR were 
collected by centrifugation and washed with water to remove the free CTAB. The seed-mediated growth 
method was also used to synthesize AuNS35 (S35), AuNS65 (S65) and AuNS115 (S115). Au seed solution 
was prepared via a chemical reduction of HAuCl4 by NaBH4 in the presence of trisodium citrate. 
Subsequently, HAuCl4 solution (30.0 mg mL
−1
, 2.25 mL), Au seed solution (75, 25 and 3.3 mL), AgNO3 
solution (5.0 mg mL
−1
, 0.9 mL) and AA solution (38.0 mg mL
−1
, 1.5 mL) was successively dropped into 75 
mL water under gentle stirring for 10 min. Usage of different volumes of Au seed solution resulted in AuNS 
having different diameter. After preparation, AuNR and AuNS solutions were mixed with an aqueous 
solution of Gel at a concentration of 0.5 (wt/v) % and the resultant solution was stirred at room temperature 
for 24 h. The gelatin-stabilized AuNPs were then collected by centrifugation, washed with water and 
re-dispersed in water for further use. 
 
4.3.3 Preparation of Gel/AuNP composite scaffolds 
An ice particulate porogen method was used to fabricate the Gel/AuNP composite scaffolds.
37-40
 At first, 
appropriate amount of Gel was dissolved in a 70% acetic acid aqueous solution to obtain an aqueous Gel 
solution at a concentration of 8.0 (wt/v)%. Subsequently, an aqueous solution of the above prepared AuNPs 
at a designated concentration was mixed with the aqueous Gel solution under sonication. The final of Au in 
the mixture solution was adjusted to 1.0 mM, 2.0 mM and 4.0 mM. The final concentration of Gel in the 
mixture solution was adjusted to 4.0 (wt/v)%. The mixture solution was placed in low temperature chamber 
at -4 
o
C for 40 min for temperature balance before mixture with ice particulates. 
Ice particulates were firstly prepared by spraying pure water into liquid nitrogen according to our 
previous work.
37-39, 41
 Ice particulates were sieved through two sieves having a mesh size of 425 and 500 µm 
to obtain ice particulates having a diameter range of 425-500 µm. The ice particulates were mixed with the 
temperature-balanced Gel/AuNP mixture solution at a weight/volume ratio of 7:3 (g/mL) at -4 
o
C. 
Subsequently, the mixture of Gel/AuNP solution and ice particulates was poured into a cooled silicone frame. 
The entire construct was frozen at -20 
o
C for 12 h and then transferred to -80 
o
C and kept there for another 4 
h. Finally, the entire set was freeze-dried for 3 d. 
After freeze-drying, the composite scaffolds were washed with ethanol to remove residual acetic acid. 
After that, the Gel/AuNP composite scaffolds were cross-linked with 50.0 mM EDC and 20.0 mM NHS 
dissolved in an ethanol aqueous solution. In order to prevent the dissolution of Gel during cross-linking and 
to maximize the cross-linking degree, three mixture solvents of ethanol and water with a decreasing ethanol 
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concentration (ethanol/water (v/v) = 95/5, 90/10 and 85/15) were used. The Gel/AuNR and Gel/AuNPs 
composite scaffolds were crosslinked sequentially by these three crosslinking solutions for 8 h each. After 
crosslinking, the composite scaffolds were rinsed with MilliQ water for 6 times and then further treated with 
0.1 M glycine for 6 h. Finally, the Gel/AuNP composite scaffolds were washed with water and freeze-dried 
for 2 d. Porous Gel scaffold was also prepared at the same conditions without adding AuNR or AuNS. The 
Gel/AuNR and Gel/AuNS composite scaffolds prepared with AuNPs having an average diameter of around 
35.0 nm, 65.0 nm and 115.0 nm were denoted as Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and 
Gel/S115, respectively. 
4.3.4 Characterization techniques 
The morphology of AuNR and AuNS was observed by transmission electron microscopy (TEM, JEOL 
2011F, Japan) with an operation voltage of 200 kV. Dynamic light scattering (DLS, ELSZ-2000, Japan) was 
used to measure the hydrodynamic size of the AuNPs. The pore structure of Gel scaffold, Gel/AuNR and 
Gel/AuNS composite scaffolds was investigated by a scanning electron microscope (SEM, Hitachi S-4800, 
Japan). The AuNP size was measured from TEM images by an Image J software. At least 100 AuNPs were 
measured for size analysis. UV-visible absorption spectra of the Gel, Gel/AuNR and Gel/AuNS scaffolds and 
the AuNPs aqueous solutions were recorded using a UV-2600 UV-visible spectrophotometer (Shimazu Corp., 
Japan). 
4.3.5 Photothermal efficiency of Gel/AuNP composite scaffolds 
The Gel/AuNP composite scaffolds and control Gel scaffold were cut into discs having a dimension of 
5.0 × 3.0 × 1.0 mm. Each of the scaffold discs was hydrated with 20 µL culture medium (EMEM) and was 
exposed to a NIR laser (805 nm, Thorlabs Inc., USA) with a power density of 1.6 W cm
-2
 for 180 s. A digital 
thermometer (AS ONE Corp., Japan) was used to measure the temperature of the samples every 10 s during 
laser irradiation. 
4.3.6 Cell culture in composite scaffolds 
Human cervical carcinoma cell line (HeLa cells) were seeded in 75 cm
2
 tissue culture flasks and 
cultured in EMEM medium supplemented with 10% FBS, penicillin (100 U mL
-1
) and streptomycin (100 μg 
mL
-1
) in 5% CO2 incubator at 37 
o
C in a humidified environment. The cells were passaged using a 0.05% 
trypsin-EDTA solution after reaching confluence. 
Before cell seeding, Gel and Gel/AuNP composite scaffolds were cut into discs (5.0 × 3.0 × 1.0 mm), 
sterilized with 70% ethanol aqueous solution for 40 min, washed with PBS for 5 times and immersed into 
culture medium at 37 
o
C for 6 h. After removing the culture medium by using a sterile tissue paper, 1 × 10
5
 
HeLa cells were seeded into each scaffold. After 5 h of incubation, the cell/scaffold constructs were 
transferred into 6-well plates and cultured in 5 mL medium in 5% CO2 incubator at 37 
o
C. 
4.3.7 Cell adhesion in composite scaffolds 
After being cultured for 1 d, cells in Gel and Gel/AuNP composite scaffold were fixed with 2.5% 
glutaraldehyde at room temperature for 2 h. And then the cell/scaffold constructs were washed with MilliQ 
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water thoroughly, frozen and freeze-dried. SEM was used to observe cell adhesion and distribution in the 
scaffolds. 
4.3.8 Photothermal ablation of HeLa cells in composite scaffolds 
After 1 d culture, the cell/scaffold constructs were divided into two groups (without or with laser 
irradiation). For laser irradiation group, the cell/scaffold constructs were taken from the culture dishes and 
exposed to the NIR laser (805 nm) for 180 s. The samples without laser irradiation were also taken out from 
incubator for 180 s to exclude environmental effects on cell viability. After laser irradiation, the cell/scaffold 
constructs were cultured for another 5 h. And then cell viability was determined by WST-1 assay. The 
absorbance at 440 nm was measured by a microplate reader (Benchmark Plus, Bio-Rad, Hercules, CA, USA). 
Every three samples were used for the measurement to calculate the average and standard deviation. 
Live/dead staining was conducted with a cellstain live-dead double staining kit to determine the live and 
dead cells in the scaffolds without or with NIR irradiation. The cell/scaffold constructs were washed twice 
with PBS and incubated in serum-free EMEM medium containing calcein AM and propidium iodide (PI) for 
15 min. After staining, the samples were observed under a fluorescent microscope (Olympus, Japan). 
4.3.9 Statistical analysis 
All of the data were presented as mean ± standard deviation (SD). Statistical analysis was performed 
using a one-way analysis of variance with Tukey’s post hoc test for multiple comparisons. A value of p < 
0.05 was considered to indicate a statistically significant difference. 
4.4 Results and Discussion 
4.4.1 Morphology of AuNPs  
The morphology and UV-Vis spectra of AuNR and AuNS with different diameter are shown in Fig.4.1. 
TEM images showed that the AuNR and AuNS had rod-like and star-like structures. The size of the three 
AuNR was (35.0 ± 6.2) × (20.4 ± 3.1), (65.9 ± 6.6) × (13.2 ± 2.2) and (117.1 ± 11.5 nm) × (27.4 ± 5.8 nm) in 
length × width, respectively. The size of the three AuNS was 37.0 ± 7.8, 66.6 ± 13.0 and 115.1 ± 24.4 nm, 
respectively. The size of the three types of AuNR and AuNS was controlled at around 35, 65 and 115 nm. 
Most of the AuNPs were found to be distributed homogeneously, which indicated the good stability of 
gelatin-stabilized AuNR and AuNS. The hydrodynamic size of R35, R65 and R115 was 35.6 ± 0.6 nm, 64.8 
± 14.8 nm and 132.4 ± 9.5 nm, respectively. The hydrodynamic size of S35, S65 and S115 was 70.0 ± 7.0 nm, 
101.4 ± 5.4 nm and 139.1 ± 8.1 nm, respectively. The hydrodynamic size of AuNPs was slightly bigger than 
that measured from TEM, which may be due to partial aggregation of AuNPs. UV-Vis spectra of AuNPs with 
different size and shape are shown in Fig. 1g and h. The absorption spectra of AuNR possessed two LSPR 
peaks, which was due to the different size in transverse and longitudinal directions of AuNR. R35, R65 and 
R115 displayed a strong longitudinal absorption peak at 611, 833 and 880 nm, respectively. AuNS showed 
abroad LSPR peak around 800 nm. The absorption peak of R65, R115, S35, S65 and S115 was located in the 
NIR region, which indicated that they should be useful for photothermal therapy.  
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Fig. 4.1. TEM image of AuNR and AuNS: (a) Rod35, (b) Rod65, (c) Rod115, (d) Star35, (e) Star65 
and (f) Star115. UV-Vis spectra of AuNR (g) and AuNS (h) in pure water.   
 
4.4.2 Porous structure of Gel and Gel/AuNP composite scaffolds 
The porous structure of Gel and Gel/AuNP composite scaffolds was observed by SEM (Fig. 4.2). Gel 
scaffold and Gel/AuNP composite scaffolds showed almost the same pore structure, which was consisted of 
spherical large pores and interconnected small pores. The size of large pores was almost equal to the size of 
ice particulates (425 ~ 500 µm) used as porogen. Formation of interconnected small pores was attributed to 
the newly formed ice crystals that formed during freezing process. The well interconnected pore structure 
should be beneficial for penetration and spatial distribution of cells throughout the scaffolds. Gross 
appearance of the corresponding composite scaffolds showed different color depending on the size, shape 
and amount of AuNPs. The color of composite scaffolds was similar to that of the corresponding aqueous 
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solution of AuNPs (Fig. 4.3). The color of composite scaffolds became darker when the amount of AuNP in 
the scaffolds increased. 
  
Fig. 4.2. SEM images of Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 composite scaffolds 
prepared with different Au concentration of (a) 1.0 mM, (b) 2.0 mM, (c) 4.0 mM and (d) control Gel scaffold. 
The inserts are gross appearance of the corresponding composite scaffolds. 
 
 
Fig. 4.3. Gross appearance of R35, R65, R115, S35, S65 and S115. 
 
High magnification SEM images (Fig. 4.4) of Gel/AuNP composite scaffolds showed that the pore 
surface became rougher after introduction of AuNPs. AuNR and AuNS were distributed homogenously on 
the walls of composite scaffolds and more AuNPs were observed with increasing AuNPs amount. 
Furthermore, single AuNR or AuNS was visible on the pore surface at a further high magnification. The 
results indicated that AuNR and AuNS could be homogenously dispersed in the composite scaffolds without 
aggregation. The homogenous distribution of AuNPs in the composite scaffolds could heat the scaffolds 
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evenly to avoid the localized over-heating resulted from nanoparticle aggregation. 
 
Fig. 4.4. Surface morphology of Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 composite 
scaffolds prepared with different Au concentration of (a) 1.0 mM, (b) 2.0 mM, (c) 4.0 mM and (d) control 
Gel scaffold. The inserts are high magnification SEM images of the corresponding scaffolds. 
 
4.4.3 Photothermal conversion efficiency of Gel/AuNP composite scaffold 
Photothermal conversion effect of Gel/AuNP composite scaffold was investigated by exposing the 
scaffolds to an 805 nm laser. The photothermal conversion effect of the different types of composite 
scaffolds was compared by the same concentration of Au used to prepare the composite scaffolds (Fig. 
4.5a-c). Temperature in the composite scaffolds during NIR laser irradiation increased with the irradiation 
time and Au concentration. Temperature change was also deeply dependent on the size and shape of AuNPs 
(Table 4.1). Gel/R65 composite scaffold showed the highest heating efficiency compared with the other five 
types of composite scaffolds. Heating efficiency of the composite scaffolds was an order of Gel/R65 > 
Gel/S65 > Gel/S35 > Gel/S115 > Gel/R115 ≈ Gel/R35. The heating efficiency of the scaffolds should be 
related to their NIR absorption properties. The UV-Vis absorption spectra of the solid phase Gel and 
Gel/AuNP composite scaffolds were measured to show their absorption properties in NIR region (Fig. 
4.5d-e). The absorption peak of composite scaffolds showed a slight red-shift as compared with their 
corresponding aqueous solution of AuNPs. There may be two reasons for the highest photothermal efficiency 
of Gel/R65. One is that the LSPR peak of Gel/R65 well matched to the common used irradiation wavelength 
for photothermal therapy. The other reason may be that the intensity of Gel/R65 UV-Vis absorption spectrum 
was higher than the other composite scaffolds, indicating the good heating effect of Gel/R65. 
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Fig. 4.5. Temperature-time curves of Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 
composite scaffolds prepared with different Au concentration of (a) 1.0 mM, (b) 2.0 mM and (c) 4.0 mM. 
The scaffolds were exposed to an 805 nm laser for 180 s. Temperature-time curve of Gel scaffold is also 
shown in (a). UV-Vis spectra of Gel/AuNR composite scaffolds (d) and Gel/AuNS composite scaffolds (e). 
 
Table 4.1. Temperature change (
o
C) of Gel and Gel/AuNP composite scaffolds after 180 s laser irradiation. 
Data represent mean ± SD. 
 
Sample 0.0 mM 1.0 mM  2.0 mM  4.0 mM  
Gel/R35 ─ 13.2 ± 1.6 16.8 ± 2.1 20.5 ± 1.3 
Gel/R65 ─ 24.2 ± 0.9 29.8 ± 0.5 33.3 ± 1.4 
Gel/R115 ─ 12.5 ± 0.7 17.6 ± 1.8 20.6 ± 1.4 
Gel/S35 ─ 16.3 ± 0.2 20.0 ± 0.8 25.8 ± 1.9 
Gel/S65 ─ 17.8 ± 1.3 21.5 ± 1.2 27.6 ± 0.7 
Gel/S115 ─ 14.3 ± 1.8 18.6 ± 0.9 23.2 ± 1.6 
Gel 7.4 ± 0.8 ─ ─ ─ 
 
4.4.4 Cell attachment in Gel/AuNP composite scaffolds 
HeLa cells were seeded in Gel and Gel/AuNP composite scaffolds to examine cell attachment. HeLa 
cells showed homogeneous distribution throughout Gel scaffold and Gel/AuNP composite scaffolds (Fig. 
4.6). The homogeneous cell distribution should be due to the interconnected pore structures of Gel and 
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Gel/AuNP composite scaffolds. High magnification images showed that many cells spread and had 
pseudopodia, which indicated cells could well adhere on the walls of Gel scaffold and Gel/AuNP composite 
scaffolds. Incorporation of AuNPs with different size and shape did not show obvious influence on cell 
adhesion, indicating the good biocompatibility of the Gel/AuNP composite scaffolds. Unlike free AuNPs in 
culture medium, the AuNR or AuNS were embedded in the gelatin matrices of the composite scaffolds. The 
coated gelatin layer improved the biocompatibility of composite scaffolds.
42
 
 
 
 
Fig. 4.6. SEM images of Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 composite scaffolds 
prepared with different Au concentration of (a) 1.0 mM, (b) 2.0 mM, (c) 4.0 mM and (d) control Gel scaffold 
after 1 d cell culture.   
 
4.4.5 Photothermal ablation of HeLa cells 
In order to investigate photothermal ablation of Gel/AuNP composite scaffolds on HeLa cells, 
cell/scaffold constructs were exposed to an NIR laser for 180 s. WST-1 was used to quantify the cell viability 
(Fig. 4.7). Without laser irradiation, cells in the Gel scaffold and Gel/AuNP composite scaffolds showed very 
high cell viability at almost the same level. When the cell/scaffold constructs were exposed to NIR laser 
irradiation, cell viability in the control Gel scaffold showed no significant change compared with that without 
laser irradiation (Fig. 4.7b). The result indicated that cellular viability in Gel scaffold did not change because 
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Gel scaffold had no photothermal therapy capability. Cell viability in Gel/R35, Gel/R115, Gel/S35, Gel/S65 
and Gel/S115 composite scaffolds decreased a little and in Gel/R65 scaffolds decreased from 97.6 ± 1.1% to 
32.3 ± 7.5% after laser irradiation when the Au concentration was 1.0 mM. Increasing the Au concentration 
to 2.0 mM, cell viability of all the Gel/AuNP scaffolds significantly decreased and cell viability of Gel/R65 
decreased to 0.4 ± 0.2%. The cell viability further decreased when the Au concentration increased to 4.0 mM. 
Cell viability in Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 composite scaffolds prepared 
at 4.0 mM of Au were 45.5 ± 8.2%, 0.2 ± 0.2%, 38.2 ± 6.4%, 20.1 ± 6.4%, 11.0 ± 3.9% and 34.9 ± 1.9%, 
respectively. The results indicated killing efficiency of Gel/AuNP composite scaffolds had an order of 
Gel/R65 > Gel/S65 > Gel/S35 > Gel/S115 > Gel/R115 > Gel/R35.   
 
 
Fig. 4.7. Viability of HeLa cells in Gel, Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and Gel/S115 
composite scaffolds without (a) or with (b) laser irradiation for 180 s. The data are presented as mean ± SD 
values. N.S., no significant difference, * p < 0.05, ** p < 0.01 and *** p < 0.001 
 
Live/dead staining was conducted to visualize the cell viability in scaffolds without or with laser 
irradiation. As shown in Fig. 4.8, almost no dead cells (indicated by red fluorescence) was observed in the 
scaffolds before laser irradiation. However, upon exposure to NIR laser, live cell number in Gel/AuNP 
composite scaffolds decreased. More and more dead cells were observed as the Au concentration in 
composite scaffolds increased. Especially, for the Gel/R65 composite scaffold, almost all the cancer cells 
were killed when the Au concentration was 2.0 mM. Furthermore, when the Au concentration was 4.0 mM, 
most of cancer cells in Gel/S65 and Gel/S35 scaffolds were killed after laser irradiation. The live/dead 
staining results were well consistent with the WST-1 results. The cancer cell killing efficiency was in the 
same order of the photothermal heating efficiency. The higher heating efficiency resulted in higher 
temperature raising to kill more cells. The Gel/R65 had the highest photothermal conversion efficiency and 
highest cancer cell ablation effect. 
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Fig. 4.8. Live/dead staining of HeLa cells in the Gel, Gel/R35, Gel/R65, Gel/R115, Gel/S35, Gel/S65 and 
Gel/S115 composite scaffolds without or with laser irradiation for 180 s. 
4.5 Conclusions 
AuNPs with tunable shape (nanorod and nanostar) and size (35.0, 65.0 and 115.0 nm) were incorporated 
into porous gelatin scaffold to function as localized PTT agents. All the Gel/AuNP composite scaffolds 
showed good biocompatibility. Local temperature in the composite scaffolds could be quickly elevated under 
NIR laser irradiation to kill the cells in the scaffolds. The photothermal efficiency and cancer cell killing 
efficiency of the composite scaffolds were highly dependent on the size and shape of AuNPs. The Gel/R65 
composite scaffold showed the highest photothermal efficiency and killing efficiency. The results will be 
useful for the design and fabrication of efficient photothermal scaffolds for cancer therapy.  
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Concluding remarks and future prospects 
 
 
 
 
5.1 Concluding remarks  
 
This thesis summarizes the design and fabrication of porous photothermal scaffolds for photothermal 
therapy application and investigates the effect of immobilized nanoparicles properties on therapeutic efficacy 
of implanted photothermal scaffolds. 
 
Chapter 1 introduces some current and new strategies, especially photothermal therapy for cancer 
therapy. Because of the limitations of free nanoparticles, porous scaffolds were explored as carriers for 
photothermal therapy application. The requirements, materials and fabrication methods of porous scaffolds 
were summarized. Finally, the objective of this study was defined. 
 
Chapter 2 describes the preparation of porous gelatin/iron oxide (Gel/Fe3O4) composite scaffolds by a 
facile ice particulates templating method. The Gel/Fe3O4 composite scaffolds could elevate the local 
temperature efficiently during laser irradiation. Cell experiment results demonstrated that the Gel/Fe3O4 
composite scaffolds had nontoxicity and showed excellent photothermal ablation ability of cancer cells. The 
composite scaffolds containing 15 wt% Fe3O4 nanoparticles could be kill almost all of the cancer cells after 
180 s laser irradiation. The Gel/Fe3O4 composite also showed the enhanced and repeatable photothermal 
ablation effect on cancer cells. The results indicated that Gel/Fe3O4 composite scaffolds should be useful for 
photothermal therapy of cancer. 
 
Chapter 3 developed a multifunctional Gel/Fe3O4-FA composite scaffold for cancer cell capture and 
ablation. A typical targeting ligand, folic acid (FA), was immobilized in the composite scaffolds by reaction 
with the excess amino groups in the scaffolds. By changing the excess amount of amino groups, the 
Gel/Fe3O4-FA composite scaffolds with different FA grafting density were also prepared. Cell capture 
experiment results showed that the cancer cells could be efficiently captured by Gel/Fe3O4-FA composite 
scaffolds and the captured cell number increased with the increasing FA amount in the composite scaffolds. 
Moreover, the Gel/Fe3O4-FA composite scaffolds also possessed excellent photothermal ablation efficiency. 
This multifunctional scaffold may provide an attractive way for specifically cancer cell capture and killing 
and supporting the subsequent cells and tissues regeneration.  
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Chapter 4 investigates the importance of immobilized nanoparticle size and shape modulation for 
photothermal therapy. AuNPs with tunable shape (gold nanorod (AuNR) and gold nanostar (AuNS)) and size 
(35.0, 65.0 and 115.0 nm) were incorporated into porous gelatin scaffold for localized PTT application. The 
photothermal efficiency and cancer cell killing efficiency of the composite scaffolds were highly dependent 
on the size and shape of AuNPs. The composite scaffold prepared with 65.0 nm Au nanorods showed the 
highest photothermal efficiency and cell killing efficiency. All the Gel/AuNS composite scaffolds with 
different AuNS sizes also had excellent photothermal efficiency and cell killing because of the broad 
absorption of AuNS in NIR region. The results highlighted the importance of shape and size modulation of 
AuNPs for PTT and may provide useful information for design and preparation of efficient photothermal 
scaffolds for cancer therapy. 
 
In conclusion, a few composite porous scaffolds of nanoparticles and gelatin were prepared for PTT 
application. By using ice particulate as porogen, a well controlled and interconnected pore structure was 
formed in the composite porous scaffolds. Fe3O4 nanoparticles could be easily immobilized in the porous Gel 
scaffolds by mixing Fe3O4 aqueous solution with gelatin solution. The Gel/Fe3O4 composite scaffolds 
possessed excellent local heating efficiency and cancer cell killing efficiency. Moreover, the therapeutic 
efficacy of Gel/Fe3O4 composite scaffolds could be enhanced by repeated heating treatment, which is 
particularly critical for their application in clinic. In order to improve the specificity to cancer cells, targeting 
ligand FA was introduced in Gel/Fe3O4 composite scaffolds. The multifunctional Gel/Fe3O4-FA composite 
scaffolds could capture cancer cells efficiently and most of cancer cells in the composite scaffolds could be 
killed during NIR laser irradiation, which indicated excellent therapeutic efficacy of Gel/Fe3O4-FA composite 
scaffolds. Another kind of very useful photothermal conversion agent, AuNP, was also immobilized in Gel 
scaffolds for PTT application. The effect of AuNPs size and shape on photothermal conversion and cancer 
cell killing were compared. The results indicated that photothermal efficiency and cancer cell killing 
efficiency of Gel/AuNP composite scaffolds highly depended on the size and shape of AuNPs. The results 
indicated the importance of shape and size modulation of AuNPs for photothermal therapy application. This 
study should contribute to the design and fabrication of efficient photothermal scaffolds for cancer therapy 
applications. 
5.2 Future prospects 
Because of the limitations of current therapies for cancer therapy application, the study described in this 
thesis was mainly focused on the design and fabrication of porous gelatin scaffold with controlled pore 
structure and photothermal conversion ability for tumor resection. The prepared different kinds of 
photothermal scaffolds had interconnected pore structure and excellent therapeutic efficacy for cancer cell 
ablation. Although all these results have proved that the immobilizing PTT agents in porous scaffold is an 
effective way for cancer therapy, the photothermal scaffolds is still far from clinical application. Therefore, 
many efforts are still needed to meet the requirements in the clinical cancer therapy application. 
 
The implanted scaffolds should possess the similar mechanical property to the implanted site to sustain 
the mechanical loading. The mechanical property has been also proved to be an important factor to effect cell 
phenotype and cell-cell interaction. Due to different mechanical strength of organs, many other kinds of 
scaffold materials should be developed to prepare photothermal scaffolds. For example, usually, Young’s 
modulus of cortical bone is about 10 GPa , while Young’s modulus of scaffolds prepared by natural polymers 
such as gelatin and collagen are much lower than the bone tissue. Therefore, photothermal scaffolds prepared 
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by ceramics or synthetic polymer may be suitable to treat the bone tumor. On the other hand, in this thesis, 
Fe3O4 nanoparticles and gold nanoparticles are incorporated into the porous scaffold for PTT application. 
Some other PTT agents can be also introduced into the porous scaffold by this facile preparation process to 
meet different application requirements and achieve better cancer cell ablation capacity.  
 
Because the malignant and resistant nature of tumor, it is important to develop effective methods for 
cancer therapy. The combination of different cancer therapy strategies could achieve better therapeutic 
efficacy and prevent cancer recurrence. For example, the anti-cancer drugs can be also loaded in the PTT 
agents and then these drug-loaded PTT agents are introduced into the porous scaffold. These photothermal 
scaffolds with controlled structure may enable the controlled and sustainable anticancer drug release and also 
possess photothermal conversion ability. The combination of chemotherapy and PTT could obtain an 
improved and repeatable effect on tumor resection. 
 
The prepared porous scaffolds in this study focus on their cancer cell killing capability. The normal cells 
can be also cultured on these scaffolds to investigate normal cell growth, migration, proliferation and 
differentiation on these composite scaffolds. Many studies have reported that nanomaterials could promote or 
inhibit the normal cell proliferation and differentiation. Therefore, the interaction between cells and 
nanomaterials in the scaffolds should be also studied. 
 
The porous photothermal scaffolds were used to in vitro cancer cell ablation. However, the cell culture 
conditions in vitro are quite different from the in vivo environment. In order to further validate the 
photothermal effect of these scaffolds in vivo environment, the photothermal scaffolds can be implanted into 
the tumor site to evaluate their tumor resection ability in vivo. More importantly, after the tumor resection, 
the subsequent surrounding normal cell growth and tissue recover should be also checked.  
 
Above all, prepare a good and suitable porous photothermal scaffold would provide a promising way for 
not only cancer therapy but also tissue engineering applications. 
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